Estrogen Resistance Syndrome

Mendelian MONDO:0014148 Pathograph 31 Show in embeddings browser Endocrine Disorder

Estrogen resistance syndrome is a rare autosomal recessive endocrine disorder caused by biallelic loss-of-function variants in ESR1, the gene encoding estrogen receptor alpha. The receptor cannot transduce estrogen at physiological concentrations, so estradiol and gonadotropins are markedly elevated while estrogen action is absent or severely reduced in bone, the reproductive tract and metabolic tissues. The truncating allele abolishes the receptor; the ligand-binding-domain alleles leave one that still responds, but only far above the physiological estradiol range. Affected individuals of both sexes show delayed bone maturation, persistently open epiphyses and osteoporosis with increased bone turnover. Most reported patients grow continuously into adulthood and are tall, but not all: the first female reported lacked the pubertal growth spurt and stayed below the 50th height percentile. Affected females lack breast development and present with primary amenorrhea, a small uterus and enlarged multicystic ovaries; the index male was normally masculinized. Impaired glucose tolerance, hyperinsulinemia and acanthosis nigricans are reported in some patients and absent in others. Estrogen administration does not reverse the skeletal phenotype. Six families have been reported in the sources cited here. The disease is distinct from aromatase deficiency, a CYP19A1 ligand-supply defect in which estradiol is low rather than high.

Ask OpenScientist

Ask a research question about Estrogen Resistance Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
7
Pathophys.
15
Phenotypes
31
Pathograph
1
Genes
3
Medical Actions
2
Differentials
2
Models
1
Deep Research
🔗

Mappings

MONDO
MONDO:0014148 estrogen resistance syndrome
skos:exactMatch MONDO
The entry and the MONDO class denote the same ESR1-defined entity. MONDO cross-references the OMIM phenotype record OMIM:615363 and Orphanet:785; OMIM:133430, which the IEMbase comparison note recorded, is the ESR1 gene record rather than the disease.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Every reported case is homozygous for its ESR1 variant, and heterozygous carriers are unaffected. Parental relatedness is documented in four of the reported families; one proband was adopted with no parental samples available, and one report does not address it.
Autosomal recessive inheritance
Show evidence (4 references)
PMID:27754803 SUPPORT Human Clinical
"The 3 affected patients carried a homozygous mutation of a highly conserved arginine 394 for which histidine was substituted through an autosomal recessive mode of transmission."
Three affected siblings homozygous for the same variant, with recessive transmission stated by the authors.
PMID:8090165 SUPPORT Human Clinical
"The patient's parents were heterozygous carriers of this mutation, and pedigree analysis revealed consanguinity."
The index case was homozygous with heterozygous, unaffected parents in a consanguineous pedigree.
PMID:18505767 SUPPORT Human Clinical
"ER-alpha heterozygosity appears to not impair spine aBMD."
Heterozygous carriers in the extended kindred had no detectable skeletal phenotype, consistent with recessive inheritance.
+ 1 more reference
⚙

Pathophysiology

7
ESR1 Loss-of-Function
Homozygous ESR1 variants abolish or severely reduce the transcriptional activity of estrogen receptor alpha. The index variant is a premature stop codon at codon 157 that truncates the receptor; the later missense variants (Q375H, E385V, R394H, M543T) sit in the ligand-binding domain and impair ligand anchoring, coactivator recruitment or nuclear translocation, so the receptor is present but cannot drive estrogen-responsive transcription.
ESR1 hgnc:3467 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ESR1 (hgnc:3467). hgnc:3467 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context variant_origin: GERMLINE zygosity: HOMOZYGOUS functional_impact_category: LOSS_OF_FUNCTION
nuclear estrogen receptor activity GO:0030284 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves nuclear estrogen receptor activity (GO:0030284), qualified as loss of function. GO:0030284 is a molecular function from the Gene Ontology. ⇓ LOSS OF FUNCTION
Animal models
Esr1-Q375H knock-in mouse (patient variant) Mouse recapitulates The patient's own missense variant reproduces receptor loss of function in vivo rather than by gene deletion.
Downstream
Loss of Estrogen Receptor Signaling in Target Tissues A receptor that cannot drive estrogen-responsive transcription leaves every estrogen-dependent tissue unresponsive to circulating estradiol.
Show evidence (4 references)
PMID:8090165 SUPPORT Human Clinical
"Direct sequencing of exon 2 revealed a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a premature stop codon."
The index lesion, a biallelic truncating variant in the receptor gene.
PMID:27754803 SUPPORT In Vitro
"Structural and functional analysis of the mutant ERα revealed strongly reduced transcriptional activity and the inability to securely anchor the activating hormone, estradiol, compared with wild-type ERα."
Functional assay of the R394H receptor showing loss of transcriptional activity and of stable ligand anchoring.
PMID:32963012 SUPPORT In Vitro
"The identity of residue 375 greatly affected the sensitivity of the receptor to agonists without changing the ligand binding affinity."
The Q375H receptor binds ligand normally but fails to couple binding to coactivator recruitment, a second molecular route to the same loss of function.
+ 1 more reference
Loss of Estrogen Receptor Signaling in Target Tissues
Cells in bone, the reproductive tract, the hypothalamic-pituitary axis and metabolic tissues receive abundant estradiol but mount no transcriptional response to it. The state is the mirror image of aromatase deficiency: the ligand is present in excess and the response is absent.
estrogen receptor signaling pathway GO:0030520 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased estrogen receptor signaling pathway (GO:0030520). GO:0030520 is a biological process from the Gene Ontology. ↓ DECREASED cellular response to estradiol stimulus GO:0071392 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cellular response to estradiol stimulus (GO:0071392). GO:0071392 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
Estrogen receptor-null mouse (alphaERKO, insertional disruption of Esr1) Mouse recapitulates Complete receptor loss with preserved viability and an unresponsive reproductive tract, the state the human disease was later shown to share.
Downstream
Loss of Estrogen Negative Feedback on the Gonadotropin Axis Hypothalamic and pituitary cells cannot register estradiol, so the negative feedback that normally restrains gonadotropin release is lost.
Failure of Epiphyseal Fusion Growth plate cells cannot execute the estrogen-dependent program of pubertal maturation and epiphyseal fusion.
Increased Bone Resorption with Failed Mineral Accrual Bone cells lose the estrogen restraint on resorption and the support for mineral accrual.
Failure of Estrogen-Dependent Female Reproductive Development Mammary, uterine and ovarian tissue cannot respond to the estradiol that would normally drive pubertal development.
Insulin Resistance and Metabolic Dysregulation Loss of estrogen receptor alpha action in metabolic tissues is followed by impaired glucose tolerance and hyperinsulinemia in some patients. The path is not established: the phenotype is absent in at least one proband, and exogenous estrogen improves insulin sensitivity in a patient whose skeleton does not respond, so a residual estrogen-responsive route in metabolic tissue is likely and unmapped.
Show evidence (2 references)
PMID:8090165 SUPPORT Human Clinical
"The patient had no detectable response to estrogen administration, despite a 10-fold increase in the serum free estradiol concentration."
Direct clinical demonstration that target tissues do not respond to estrogen even at supraphysiological exposure.
PMID:42734155 SUPPORT REVIEW SYNTHESIS Other
"In contrast, germline ESR1 mutations cause EIS by impairing ERα function and rendering peripheral tissues insensitive to circulating E2."
Review statement of the tissue-level consequence of germline receptor loss, contrasted with somatic activating mutations in breast cancer.
Loss of Estrogen Negative Feedback on the Gonadotropin Axis
Without receptor-mediated estrogen feedback, follicle-stimulating and luteinizing hormone secretion is disinhibited. Gonadotropins rise, the gonads are driven to produce estradiol, and estradiol accumulates to many times the normal range because nothing downstream registers it. In females the sustained gonadotropin drive produces enlarged multicystic ovaries.
negative regulation of gonadotropin secretion GO:0032277 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent negative regulation of gonadotropin secretion (GO:0032277). GO:0032277 is a biological process from the Gene Ontology. ∅ ABSENT gonadotropin secretion GO:0032274 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased gonadotropin secretion (GO:0032274). GO:0032274 is a biological process from the Gene Ontology. ↑ INCREASED
hypothalamus UBERON:0001898 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in hypothalamus (UBERON:0001898). UBERON:0001898 is an anatomical location from the Uberon multi-species anatomy ontology. pituitary gland UBERON:0000007 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in pituitary gland (UBERON:0000007). UBERON:0000007 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Elevated circulating follicle stimulating hormone level Disinhibited FSH secretion.
Elevated circulating luteinizing hormone level Disinhibited LH secretion.
Increased serum estradiol Gonadotropin-driven estradiol production that nothing downstream registers.
Enlarged polycystic ovaries Unrestrained gonadotropin stimulation of ovaries that cannot respond to their own estradiol produces enlarged multicystic ovaries. This is the ovarian arm, distinct from the receptor's direct failure in breast and uterus, which reaches those tissues without passing through the gonadotropin axis.
Show evidence (3 references)
PMID:8090165 SUPPORT Human Clinical
"Serum estradiol and estrone concentrations were elevated, and serum testosterone concentrations were normal. Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
The defining endocrine signature in the index male, high estrogens with high gonadotropins and normal testosterone.
PMID:27754803 SUPPORT Human Clinical
"Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
Quantifies the estradiol and gonadotropin elevation across three siblings.
PMID:32152632 SUPPORT Human Clinical
"Luteinizing hormone (LH) pulse studies demonstrated normal pulsatile LH secretion, elevated mean LH, and mildly elevated mean follicle-stimulating hormone (FSH) in the presence of markedly increased estrogens."
Pulse studies show the axis is intact in pattern and raised in level, which is what loss of feedback rather than a hypothalamic lesion predicts.
Failure of Epiphyseal Fusion
Estrogen acting through estrogen receptor alpha drives growth plate maturation and epiphyseal fusion at puberty. Without receptor signalling bone age lags chronological age by years and the epiphyses stay open, so linear growth continues into adulthood in most reported patients. The pubertal growth spurt itself is estrogen-driven and is absent, which is why continued growth does not always produce tall stature.
growth plate chondrocyte CL:0000138 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves growth plate chondrocyte, annotated with chondrocyte (CL:0000138). CL:0000138 is a cell type from the Cell Ontology.
growth plate cartilage development GO:0003417 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal growth plate cartilage development (GO:0003417). GO:0003417 is a biological process from the Gene Ontology. ⚠ ABNORMAL
epiphyseal plate UBERON:0002516 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in epiphyseal plate (UBERON:0002516). UBERON:0002516 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Tall stature Continued linear growth from unfused epiphyses in most reported patients.
Delayed skeletal maturation Bone age lags chronological age by years.
Absent pubertal growth spurt The estrogen-driven pubertal acceleration of growth velocity does not occur.
Show evidence (3 references)
PMID:8090165 SUPPORT Human Clinical
"had incomplete epiphyseal closure, with a history of continued linear growth into adulthood despite otherwise normal pubertal development."
Open epiphyses and continued growth in an adult male with the receptor lesion.
PMID:9554463 SUPPORT REVIEW SYNTHESIS Human Clinical
"However, they lead to absence of the pubertal growth spurt, delayed bone maturation, unfused epiphyses, continued growth into adulthood and very tall adult stature in both sexes."
Review synthesis of the growth-plate consequence shared by estrogen resistance and aromatase deficiency, which places the lesion in estrogen action on the epiphysis.
PMID:18505767 SUPPORT Human Clinical
"Bone age advanced from 15-17.5 yr."
Bone age in the index male remained in the mid-teens across a follow-up spanning his late twenties to early thirties.
Increased Bone Resorption with Failed Mineral Accrual
Estrogen receptor alpha signalling restrains osteoclastic resorption and supports mineral accrual. Without it, trabecular and cortical bone are markedly undermineralized with a high-turnover signature on biopsy and raised turnover markers, and bone density continues to fall in adulthood despite estrogen or selective estrogen receptor modulator treatment. Periosteal circumference is spared.
osteoclast CL:0000092 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoclast (CL:0000092). CL:0000092 is a cell type from the Cell Ontology.
bone resorption GO:0045453 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased bone resorption (GO:0045453). GO:0045453 is a biological process from the Gene Ontology. ↑ INCREASED bone mineralization GO:0030282 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased bone mineralization (GO:0030282). GO:0030282 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Osteoporosis Undermineralized, high-turnover bone.
Show evidence (4 references)
PMID:8090165 SUPPORT Human Clinical
"The bone mineral density of the lumbar spine was 0.745 g per square centimeter, 3.1 SD below the mean for age-matched normal women; there was biochemical evidence of increased bone turnover."
Undermineralized bone with a high-turnover signature.
PMID:18505767 SUPPORT Human Clinical
"Homozygous ER-alpha disruption markedly affects bone growth, mineral content, and structure but not periosteal circumference."
Bone biopsy and quantitative computed tomography of the index case define the skeletal lesion and its one spared compartment.
PMID:40032016 SUPPORT Human Clinical
"Markers of bone turnover were increased and unresponsive to treatment."
The same high-turnover skeletal state in a female with a ligand-binding-domain variant, unchanged by estrogen or tamoxifen.
+ 1 more reference
Failure of Estrogen-Dependent Female Reproductive Development
Breast development and uterine growth at puberty require estrogen receptor alpha, so affected females have no breast development, a small uterus and primary amenorrhea despite very high estradiol. This node is the receptor's direct failure in those target tissues. The ovarian enlargement of this disease is a separate mechanism and hangs off the gonadotropin-feedback node instead, because it is driven by unopposed gonadotropins rather than by the missing estrogen signal in the ovary.
mammary gland development GO:0030879 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent mammary gland development (GO:0030879). GO:0030879 is a biological process from the Gene Ontology. ∅ ABSENT
mammary gland UBERON:0001911 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in mammary gland (UBERON:0001911). UBERON:0001911 is an anatomical location from the Uberon multi-species anatomy ontology. uterus UBERON:0000995 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in uterus (UBERON:0000995). UBERON:0000995 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Breast aplasia No pubertal breast development despite high estradiol.
Primary amenorrhea No menarche.
Hypoplasia of the uterus Loss of the estrogen drive on uterine growth.
Delayed puberty Failure to enter estrogen-dependent puberty in females.
Show evidence (2 references)
PMID:23841731 SUPPORT Human Clinical
"This case shows that disruption of ESR1 causes profound estrogen resistance in women."
The first female case establishes the reproductive phenotype as a consequence of ESR1 disruption.
PMID:39295121 SUPPORT Human Clinical
"Here, the case of a 13-year-old girl, with high estrogen and gonadotropin concentrations, lack of breast development, uterine growth and delayed bone age is described."
Breast and uterine failure together in one patient, which is the pair of target tissues this node is now scoped to.
Insulin Resistance and Metabolic Dysregulation
Loss of estrogen receptor alpha action is accompanied by impaired glucose tolerance, hyperinsulinemia, reduced insulin sensitivity, raised leptin and axillary acanthosis nigricans. Exogenous ethinyl-estradiol improved insulin sensitivity in one long-term follow-up even though it did not help bone, suggesting a residual estrogen-responsive route in metabolic tissue that is absent in the skeleton.
cellular response to insulin stimulus GO:0032869 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cellular response to insulin stimulus (GO:0032869). GO:0032869 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Impaired glucose tolerance Reduced insulin action on glucose disposal.
Hyperinsulinemia Compensatory insulin excess.
Acanthosis nigricans Cutaneous marker of hyperinsulinemia.
Show evidence (4 references)
PMID:8090165 SUPPORT Human Clinical
"Glucose tolerance was impaired, and hyperinsulinemia was present."
The metabolic phenotype in the index case.
PMID:40032016 SUPPORT Human Clinical
"The metabolic phenotype included insulin resistance, decreased insulin sensitivity and increased leptinemia."
The same metabolic picture in a female case with eight years of follow-up.
PMID:23841731 REFUTE Human Clinical
"Our patient had normal levels of fasting glucose, insulin, and glycated hemoglobin and a normal HOMA-IR, indicating no impaired glucose tolerance."
Refutes the metabolic phenotype as a constant feature. The Q375H proband had normal fasting glucose, insulin, glycated hemoglobin and insulin resistance index, which is why the node and the entry description report it in some patients rather than all.
+ 1 more reference
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Estrogen Resistance Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

15
Breast 1
Breast aplasia HP:0100783 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent breast development, annotated with Breast aplasia (HP:0100783). HP:0100783 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35134944 SUPPORT Human Clinical
"A 36-year-old woman from a consanguineous Jordanian family presented with primary amenorrhea and no breast development, with high plasma levels of 17β-estradiol (E2), follicle-stimulating hormone and luteinizing hormone, and enlarged multifollicular ovaries, strongly suggesting estrogen resistance."
Absent breast development together with the defining hormonal picture.
Endocrine 5
Delayed puberty HP:0000823 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed puberty (HP:0000823). HP:0000823 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35134944 SUPPORT Human Clinical
"Her 18-year-old sister did not enter puberty and had moderately high levels of E2, high plasma gonadotropin levels, and normal ovaries."
Absent puberty in an affected female.
Elevated circulating follicle stimulating hormone level HP:0008232 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated FSH, annotated with Elevated circulating follicle stimulating hormone level (HP:0008232). HP:0008232 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:8090165 SUPPORT Human Clinical
"Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
Elevated gonadotropins in the index male.
Elevated circulating luteinizing hormone level HP:0011969 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated LH, annotated with Elevated circulating luteinizing hormone level (HP:0011969). HP:0011969 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:8090165 SUPPORT Human Clinical
"Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
Elevated gonadotropins in the index male.
Increased serum estradiol HP:0025134 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Markedly elevated serum estradiol, annotated with Increased serum estradiol (HP:0025134). HP:0025134 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27754803 SUPPORT Human Clinical
"Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
Quantified estradiol elevation across three siblings.
Hyperinsulinemia HP:0000842 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperinsulinemia (HP:0000842). HP:0000842 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:8090165 SUPPORT Human Clinical
"Glucose tolerance was impaired, and hyperinsulinemia was present."
Hyperinsulinemia in the index case.
PMID:40032016 SUPPORT Human Clinical
"The metabolic phenotype included insulin resistance, decreased insulin sensitivity and increased leptinemia."
Insulin resistance in a female case.
Genitourinary 3
Primary amenorrhea HP:0000786 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Primary amenorrhea (HP:0000786). HP:0000786 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35134944 SUPPORT Human Clinical
"A 36-year-old woman from a consanguineous Jordanian family presented with primary amenorrhea and no breast development, with high plasma levels of 17β-estradiol (E2), follicle-stimulating hormone and luteinizing hormone, and enlarged multifollicular ovaries, strongly suggesting estrogen resistance."
Primary amenorrhea in an adult female case.
Hypoplasia of the uterus HP:0000013 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Small uterus, annotated with Hypoplasia of the uterus (HP:0000013). HP:0000013 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23841731 SUPPORT Human Clinical
"Ultrasonography revealed a small uterus with no clearly identifiable endometrial stripe and markedly enlarged multicystic ovaries"
Imaging of the uterus and ovaries in the first female case.
Enlarged polycystic ovaries HP:0008675 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Enlarged multicystic ovaries, annotated with Enlarged polycystic ovaries (HP:0008675). HP:0008675 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:23841731 SUPPORT Human Clinical
"We now describe an 18-year-old woman without breast development and with markedly elevated serum levels of estrogens and bilateral multicystic ovaries."
Bilateral multicystic ovaries in the first female case.
PMID:27754803 SUPPORT Human Clinical
"The 2 sisters had enlarged multicystic ovaries."
Enlarged multicystic ovaries in two further females.
Integument 1
Acanthosis nigricans HP:0000956 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Axillary acanthosis nigricans, annotated with Acanthosis nigricans (HP:0000956). HP:0000956 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:8090165 SUPPORT Human Clinical
"He was normally masculinized and had bilateral axillary acanthosis nigricans."
Acanthosis nigricans in the index male.
PMID:40032016 SUPPORT Human Clinical
"She had no breast development, normal axillary and pubic pilosity and bilateral axillary acanthosis nigricans."
The same finding in a female case.
Metabolism 1
Impaired glucose tolerance HP:0040270 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Impaired glucose tolerance (HP:0040270). HP:0040270 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:8090165 SUPPORT Human Clinical
"Glucose tolerance was impaired, and hyperinsulinemia was present."
Impaired glucose tolerance in the index case.
Musculoskeletal 2
Delayed skeletal maturation HP:0002750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed bone age with persistently open epiphyses, annotated with Delayed skeletal maturation (HP:0002750). HP:0002750 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27754803 SUPPORT Human Clinical
"An ESR1 mutation was identified in 2 sisters and 1 brother, originating from a consanguineous Algerian family, who did not enter puberty and presented with delayed bone maturation consistent with estrogen insensitivity."
Delayed bone maturation in all three affected siblings.
PMID:18505767 SUPPORT Human Clinical
"Bone age advanced from 15-17.5 yr."
Bone age in the index male remained in the mid-teens across a follow-up spanning his late twenties to early thirties.
Osteoporosis HP:0000939 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:40032016 SUPPORT Human Clinical
"She had a severe osteoporosis of the lumbar spine (Z-score -3.9) and osteopenia of the femoral neck (Z-score -1.8)."
Densitometric osteoporosis in a female case.
PMID:18505767 SUPPORT Human Clinical
"Bone biopsy revealed marked osteopenia (cortex: 641 microm), low trabecular volume (10.6%), decreased thickness (76.2 microm), normal trabecular number, and low activation frequency (0.099/yr)."
Histomorphometric confirmation in the index male.
Growth 2
Tall stature HP:0000098 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tall stature (HP:0000098). HP:0000098 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:40032016 SUPPORT Human Clinical
"The patient, first seen at the age of 21.3 years, presented with a tall stature (+2.2 SD), a delayed bone age (13 years)."
Tall stature with delayed bone age in a female case.
PMID:8090165 SUPPORT Human Clinical
"The patient was tall (204 cm"
The height of the index male, which the description quotes. Truncated before the parenthetical imperial conversion, since bracketed spans are stripped before snippet matching.
PMID:23841731 REFUTE Human Clinical
"Her growth velocity indicated the lack of an estrogen-induced growth spurt at the time of puberty"
Refutes tall stature as a constant feature. This proband had no estrogen-driven pubertal acceleration and remained below the 50th height percentile, which is why the description reports tall stature in most patients rather than all.
Absent pubertal growth spurt HP:0031087 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent pubertal growth spurt (HP:0031087). HP:0031087 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:9554463 SUPPORT REVIEW SYNTHESIS Human Clinical
"However, they lead to absence of the pubertal growth spurt, delayed bone maturation, unfused epiphyses, continued growth into adulthood and very tall adult stature in both sexes."
Review synthesis naming the absent growth spurt in both estrogen resistance and aromatase deficiency.
PMID:23841731 SUPPORT Human Clinical
"Her growth velocity indicated the lack of an estrogen-induced growth spurt at the time of puberty"
Growth velocity in the Q375H proband shows the missing estrogen-driven spurt.
🧬

Genetic Associations

1
ESR1
Gene: ESR1 hgnc:3467 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ESR1 (hgnc:3467). hgnc:3467 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (3 references)
PMID:8090165 SUPPORT Human Clinical
"Direct sequencing of exon 2 revealed a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a premature stop codon."
The index biallelic truncating variant.
PMID:23841731 SUPPORT Human Clinical
"She was found to have a homozygous loss-of-function ESR1 mutation in a completely conserved residue that interferes with estrogen signaling."
The first female case, homozygous for a missense variant.
PMID:39295121 SUPPORT Human Clinical
"She was found to have a homozygous pathogenic variant in the ESR1 gene located on chromosome 6q25, which interferes with estrogen signaling."
The sixth reported family, homozygous at the ESR1 locus. Cited for the variant and the locus only; this report's abstract also calls the syndrome autosomal dominant, which its own homozygous finding and related parents contradict, so it is not used for inheritance.
💊

Medical Actions

3
Estrogen Administration
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: estradiol CHEBI:23965 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses estradiol (CHEBI:23965). CHEBI:23965 is a therapeutic agent from Chemical Entities of Biological Interest. ethinylestradiol CHEBI:4903 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ethinylestradiol, annotated with 17alpha-ethynylestradiol (CHEBI:4903). CHEBI:4903 is a therapeutic agent from Chemical Entities of Biological Interest. diethylstilbestrol CHEBI:41922 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses diethylstilbestrol (CHEBI:41922). CHEBI:41922 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Estrogen given to test or overcome the resistance. Transdermal estradiol for six months produced no detectable response in the index male, and ethinyl-estradiol followed by tamoxifen did not arrest bone loss in a female followed for eight years. Ethinyl-estradiol did improve insulin sensitivity, lower leptin and raise some estrogen-regulated liver proteins in that patient, so a partial metabolic benefit is documented while the skeletal phenotype is not treatable by this route. No effective therapy for the bone disease is known.
Mechanism Target:
Insulin Resistance and Metabolic Dysregulation — Ethinyl-estradiol improved insulin sensitivity and lowered leptin in one long-term follow-up.
Show evidence (1 reference)
PMID:40032016 SUPPORT Human Clinical
"Treatment with ethinyl-estradiol improved insulin sensitivity, lowered leptinemia, increased some estrogen-regulated liver proteins and the E2/T ratio."
The one documented benefit of estrogen administration in this disease.
Show evidence (6 references)
PMID:8090165 REFUTE Human Clinical
"The patient had no detectable response to estrogen administration, despite a 10-fold increase in the serum free estradiol concentration."
Refutes estrogen administration as a treatment of the resistance itself in the index case.
PMID:40032016 REFUTE Human Clinical
"Osteoporosis worsened (Z-score -5.6 at the lumbar spine; Z-score -4.4 at the femoral neck) despite successive treatments with ethinyl-estradiol and tamoxifen (selective estrogen modulator)."
Refutes estrogen administration as treatment of the skeletal disease. The same sentence also refutes the selective estrogen receptor modulator given after it, which is recorded as its own treatment below.
PMID:40032016 SUPPORT BACKGROUND Human Clinical
"To date, there are no effective therapeutic options."
States the therapeutic gap that this treatment record documents.
+ 3 more references
Selective Estrogen Receptor Modulator Therapy
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: tamoxifen CHEBI:41774 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses tamoxifen (CHEBI:41774). CHEBI:41774 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Tamoxifen was given after ethinyl-estradiol failed in the eight-year follow-up, on the rationale that a modulator might engage a receptor that estradiol could not. Bone loss continued through it. Recorded separately from estrogen administration because a selective modulator is a different pharmacological class, not a dose of estrogen.
Show evidence (1 reference)
PMID:40032016 REFUTE Human Clinical
"Osteoporosis worsened (Z-score -5.6 at the lumbar spine; Z-score -4.4 at the femoral neck) despite successive treatments with ethinyl-estradiol and tamoxifen (selective estrogen modulator)."
Refutes the selective estrogen receptor modulator as treatment of the skeletal disease; bone density fell further while it was given.
Progestin Suppression of Gonadotropin-Driven Ovarian Enlargement
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: norethisterone CHEBI:7627 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses norethisterone (CHEBI:7627). CHEBI:7627 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Norethisterone given to the first female case was temporally associated with falling estradiol and with reduction in ovarian volume and cyst number, which returned when it was stopped. The progesterone receptor is intact in this disease, so progestin feedback can restrain the gonadotropin drive that the absent estrogen feedback releases. This is the only reported intervention that changes a phenotype here, and it addresses the ovarian consequence rather than the receptor defect.
Mechanism Target:
Loss of Estrogen Negative Feedback on the Gonadotropin Axis — Progesterone-receptor-mediated negative feedback substitutes for the absent estrogen feedback and lowers the gonadotropin drive on the ovary.
Show evidence (1 reference)
PMID:23841731 SUPPORT Human Clinical
"In addition, the administration of norethindrone was temporally associated with reductions in ovarian volume and number of cysts, which suggests that negative feedback mediated by progesterone receptor was intact."
The authors read the ovarian response as evidence that progesterone-receptor-mediated negative feedback was intact, which is the mechanism this treatment acts through.
Show evidence (1 reference)
PMID:23841731 SUPPORT Human Clinical
"In addition, the administration of norethindrone was temporally associated with reductions in ovarian volume and number of cysts, which suggests that negative feedback mediated by progesterone receptor was intact."
A single-patient, uncontrolled observation with an on-and-off course, which is why the treatment is recorded as documented rather than established.
🔬

Biochemical Markers

4
Serum Estradiol (INCREASED)
Context: Estradiol is markedly elevated, up to more than fifty-fold the normal range, because gonadotropin drive is unrestrained and the hormone is not registered by its receptor.
Pathograph Readouts
Readout Of Loss of Estrogen Negative Feedback on the Gonadotropin Axis Positive Diagnostic
High estradiol with high gonadotropins distinguishes receptor resistance from aromatase deficiency, where estradiol is low.
Show evidence (1 reference)
PMID:27754803 SUPPORT Human Clinical
"Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
The authors read the combination as the diagnostic signature of estrogen resistance.
Show evidence (1 reference)
PMID:8090165 SUPPORT Human Clinical
"Serum estradiol and estrone concentrations were elevated, and serum testosterone concentrations were normal."
Elevated estradiol in the index case.
Estrogen-Regulated Hepatic Binding Proteins (NORMAL)
Context: Corticosteroid-binding, sex-hormone-binding and thyroxine-binding globulins are not raised despite markedly elevated estrogen, which is the hepatic readout of the resistance itself: in any state of true estrogen excess these proteins rise.
Pathograph Readouts
Readout Of Loss of Estrogen Receptor Signaling in Target Tissues Negative Diagnostic
Unchanged estrogen-regulated hepatic proteins in the presence of high estradiol report that the hormone is not being transduced.
Show evidence (1 reference)
PMID:23841731 SUPPORT Human Clinical
"Serum levels of corticosteroid-binding globulin, sex-hormone–binding globulin, thyroxine-binding globulin, prolactin, and triglycerides were not increased, despite elevated estrogen levels."
The measurement behind this readout, and the cleanest biochemical demonstration that target tissues do not register the circulating hormone.
Serum Follicle-Stimulating Hormone (INCREASED)
Context: FSH is elevated from loss of estrogen negative feedback.
Pathograph Readouts
Readout Of Loss of Estrogen Negative Feedback on the Gonadotropin Axis Positive Diagnostic
Elevated FSH reports the disinhibited gonadotropin axis.
Show evidence (1 reference)
PMID:8090165 SUPPORT Human Clinical
"Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
Elevated FSH in the index case.
Show evidence (1 reference)
PMID:27754803 SUPPORT Human Clinical
"Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
Gonadotropins above threefold the normal range across three siblings.
Serum Luteinizing Hormone (INCREASED)
Context: LH is elevated from loss of estrogen negative feedback.
Pathograph Readouts
Readout Of Loss of Estrogen Negative Feedback on the Gonadotropin Axis Positive Diagnostic
Elevated LH reports the disinhibited gonadotropin axis.
Show evidence (1 reference)
PMID:8090165 SUPPORT Human Clinical
"Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
Elevated LH in the index case.
Show evidence (1 reference)
PMID:35134944 SUPPORT Human Clinical
"Her 18-year-old sister did not enter puberty and had moderately high levels of E2, high plasma gonadotropin levels, and normal ovaries."
High gonadotropins even in the milder sister.
🔬

Diagnosis

1
ESR1 Sequencing with the High-Estradiol, High-Gonadotropin Profile (Positive in affected individuals)
The biochemical signature is markedly elevated estradiol together with elevated gonadotropins, which separates receptor resistance from aromatase deficiency: in that disease the same high gonadotropins accompany low or undetectable estradiol. Estrogen-regulated hepatic binding proteins are not raised despite the high estradiol, which is the confirmatory sign that the hormone is not being transduced. Diagnosis is completed by ESR1 sequencing, which in every reported case shows a homozygous variant.
Show evidence (3 references)
PMID:27754803 SUPPORT Human Clinical
"Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
The authors read this combination as the diagnostic signature of estrogen resistance, which is what this record is built on.
PMID:23841731 SUPPORT Human Clinical
"Serum levels of corticosteroid-binding globulin, sex-hormone–binding globulin, thyroxine-binding globulin, prolactin, and triglycerides were not increased, despite elevated estrogen levels."
The confirmatory hepatic sign: in any state of true estrogen excess these proteins rise, so unchanged levels alongside high estradiol demonstrate that the hormone is not being transduced.
PMID:39295121 SUPPORT Human Clinical
"She was found to have a homozygous pathogenic variant in the ESR1 gene located on chromosome 6q25, which interferes with estrogen signaling."
Genetic confirmation by ESR1 sequencing in a patient presenting with the profile above.
📈

Progression

2
Onset
Age: Adolescence to young adulthood
Females present with absent pubertal breast development and primary amenorrhea in adolescence; the index male, normally masculinized, was recognised at 28 years from continued linear growth and open epiphyses.
Show evidence (2 references)
PMID:23841731 SUPPORT Human Clinical
"We now describe an 18-year-old woman without breast development and with markedly elevated serum levels of estrogens and bilateral multicystic ovaries."
Adolescent presentation with failed pubertal development in a female.
PMID:8090165 SUPPORT Human Clinical
"A 28-year-old man whose estrogen resistance was caused by a disruptive mutation in the estrogen-receptor gene underwent studies of pituitary-gonadal function and bone density and received transdermal estrogen for six months."
The index male was identified in adulthood.
Course
Age: Adulthood
Linear growth continues into the third decade and bone mineral density falls further despite estrogen or selective estrogen receptor modulator treatment.
Show evidence (2 references)
PMID:40032016 SUPPORT Human Clinical
"The patient presented a continuous linear growth (height + 3SD at the age of 28.6 years)."
Eight-year follow-up documents ongoing growth into the late twenties.
PMID:18505767 SUPPORT Human Clinical
"Spine aBMD at age 28.5 yr (0.745 g/cm(2)) decreased to 0.684 g/cm(2) (Z score -3.85) in 3.5 yr."
Longitudinal bone loss in the index male over three and a half years.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
Reported cases are counted in families rather than in rates. Five patients from three families were known by 2022; the two sisters reported that year, an adolescent girl in 2024 and a woman with a ligand-binding-domain variant in 2025 bring the cited total to six families. No population estimate exists.
Show evidence (1 reference)
PMID:35134944 SUPPORT Human Clinical
"Only 3 females and 2 males, from 3 families, with a loss of ERα function have been reported to date."
A literature count at the time of the fourth family's report.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Estrogen Resistance Syndrome:

Aromatase deficiency
Overlapping Features The ligand-supply counterpart: CYP19A1 loss leaves estradiol low or undetectable with high gonadotropins, and the skeletal phenotype of tall stature, open epiphyses and osteoporosis overlaps. Estradiol level separates the two, and estrogen replacement is effective in aromatase deficiency but not here.
Show evidence (3 references)
PMID:11305285 SUPPORT REVIEW SYNTHESIS Other
"Thus far, one estrogen-resistant human, a man with a mutant estrogen receptor-alpha gene, has been described. His clinical presentation was similar to that of aromatase-deficient men."
The clinical overlap that makes aromatase deficiency the principal differential.
PMID:34538723 SUPPORT REVIEW SYNTHESIS Other
"Germline loss-of-function variants in ESR1, the gene encoding estrogen receptor α, are known to cause of estrogen insensitivity/resistance."
Places the two diseases side by side as the biosynthesis and action arms of congenital estrogen disorders; the sentence is quoted as the source prints it.
PMID:9554463 SUPPORT REVIEW SYNTHESIS Human Clinical
"Gonadotropin and androgen levels are elevated in patients with either estrogen deficiency (aromatase deficiency) or estrogen resistance (estrogen receptor mutation)."
The shared gonadotropin elevation; estradiol, low in one and high in the other, is what separates them.
🐁

Animal Models

2
Estrogen receptor-null mouse (alphaERKO, insertional disruption of Esr1)
The first receptor-null mouse. Both sexes survive with normal external phenotypes; females are infertile with hypoplastic uteri and hyperemic ovaries lacking corpora lutea, and their uteri do not respond to estradiol.
Species
Mouse
Genotype
Esr1 insertional disruption, homozygous
Publication
PMID:8248223
Pathograph links
Loss of Estrogen Receptor Signaling in Target Tissues recapitulates fidelity: high observes: organism Complete receptor loss with preserved viability and an unresponsive reproductive tract, the state the human disease was later shown to share.
Limitations: Insertional disruption rather than a patient variant; the mouse lacks the continued longitudinal growth of humans with open epiphyses, since rodent growth plates do not fuse.
Readouts
Uterine wet weight response to estradiol
Direction: ABOLISHED
Interpretation: Tissue-level estrogen responsiveness is absent in the receptor-null animal.
Show evidence (1 reference)
PMID:8248223 SUPPORT Model Organism
"In adult wild-type and heterozygous females, 3-day estradiol treatment at 40 micrograms/kg stimulates a 3- to 4-fold increase in uterine wet weight and alters vaginal cornification, but the uteri and vagina do not respond in the animals with the estrogen receptor gene disruption."
The measurement behind the readout.
Show evidence (1 reference)
PMID:8248223 SUPPORT Model Organism
"We have generated mutant mice lacking responsiveness to estradiol by disrupting the estrogen receptor gene by gene targeting."
The model is defined by loss of estradiol responsiveness, which is the node's claim.
Show evidence (1 reference)
PMID:8248223 SUPPORT Model Organism
"Both male and female animals survive to adulthood with normal gross external phenotypes. Females are infertile; males have a decreased fertility."
Viability and the reproductive phenotype of the receptor-null mouse.
Esr1-Q375H knock-in mouse (patient variant)
A mouse carrying the human Q375H variant. Both sexes are infertile with phenotypes resembling the receptor-null mouse and corresponding to the patient the variant came from.
Species
Mouse
Genotype
Esr1 p.Gln375His homozygous, CRISPR/Cas9 knock-in
Publication
PMID:32242619
Pathograph links
ESR1 Loss-of-Function recapitulates fidelity: high observes: organism The patient's own missense variant reproduces receptor loss of function in vivo rather than by gene deletion.
Limitations: Reported phenotypes are reproductive; skeletal and metabolic features of the human disease are not described in the abstract.
Readouts
Fertility of homozygous Q375H knock-in mice
Direction: ABOLISHED
Interpretation: Both sexes are infertile, the same outcome as receptor deletion, which is what marks the patient's missense allele as a loss of function in vivo.
Show evidence (1 reference)
PMID:32242619 SUPPORT Model Organism
"Female and male Esr1-Q mice are infertile and have similar phenotypes to αERKO mice."
The measured outcome behind this readout.
Show evidence (1 reference)
PMID:32242619 SUPPORT Model Organism
"Female and male Esr1-Q mice are infertile and have similar phenotypes to αERKO mice."
The knock-in phenocopies the receptor-null animal.
Show evidence (1 reference)
PMID:32242619 SUPPORT Model Organism
"Furthermore, we generated a mouse model Esr1-Q harboring the human mutation using CRISPR/Cas9 genome editing."
The model's construction from the patient variant.
{ }

Source YAML

click to show 
name: Estrogen Resistance Syndrome
creation_date: "2026-09-29T20:30:00Z"
description: >-
  Estrogen resistance syndrome is a rare autosomal recessive endocrine disorder
  caused by biallelic loss-of-function variants in ESR1, the gene encoding
  estrogen receptor alpha. The receptor cannot transduce estrogen at
  physiological concentrations, so estradiol and gonadotropins are markedly
  elevated while estrogen action is absent or severely reduced in bone, the
  reproductive tract and metabolic tissues. The truncating allele abolishes the
  receptor; the ligand-binding-domain alleles leave one that still responds,
  but only far above the physiological estradiol range. Affected individuals of
  both sexes show delayed bone maturation, persistently open epiphyses and
  osteoporosis with increased bone turnover. Most reported patients grow
  continuously into adulthood and are tall, but not all: the first female
  reported lacked the pubertal growth spurt and stayed below the 50th height
  percentile. Affected females lack breast development and present with primary
  amenorrhea, a small uterus and enlarged multicystic ovaries; the index male
  was normally masculinized. Impaired glucose tolerance, hyperinsulinemia and
  acanthosis nigricans are reported in some patients and absent in others. Estrogen administration
  does not reverse the skeletal phenotype. Six families have been reported in
  the sources cited here. The disease is distinct from aromatase deficiency, a CYP19A1
  ligand-supply defect in which estradiol is low rather than high.
synonyms:
- estrogen resistance
- ESTRR
- oestrogen insensitivity
- oestrogen resistance
- estrogen insensitivity syndrome
- EIS
category: Mendelian
parents:
- Endocrine Disorder
disease_term:
  preferred_term: estrogen resistance syndrome
  description: >-
    Rare genetic endocrine disease of estrogen receptor insensitivity with
    elevated estrogen and gonadotropin serum levels.
  term:
    id: MONDO:0014148
    label: estrogen resistance syndrome
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0014148
      label: estrogen resistance syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      The entry and the MONDO class denote the same ESR1-defined entity. MONDO
      cross-references the OMIM phenotype record OMIM:615363 and Orphanet:785;
      OMIM:133430, which the IEMbase comparison note recorded, is the ESR1 gene
      record rather than the disease.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Every reported case is homozygous for its ESR1 variant, and heterozygous
    carriers are unaffected. Parental relatedness is documented in four of the
    reported families; one proband was adopted with no parental samples
    available, and one report does not address it.
  evidence:
  - reference: PMID:27754803
    reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The 3 affected patients carried a homozygous mutation of a highly conserved arginine 394 for which histidine was substituted through an autosomal recessive mode of transmission."
    explanation: Three affected siblings homozygous for the same variant, with recessive transmission stated by the authors.
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient's parents were heterozygous carriers of this mutation, and pedigree analysis revealed consanguinity."
    explanation: The index case was homozygous with heterozygous, unaffected parents in a consanguineous pedigree.
  - reference: PMID:18505767
    reference_title: "Impact on bone of an estrogen receptor-alpha gene loss of function mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ER-alpha heterozygosity appears to not impair spine aBMD."
    explanation: Heterozygous carriers in the extended kindred had no detectable skeletal phenotype, consistent with recessive inheritance.
  - reference: PMID:39295121
    reference_title: "Estrogen-insensitivity syndrome (EIS) in a female adolescent patient - a case report."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Estrogen insensitivity syndrome (EIS) is a rare genetic disorder characterized by an autosomal dominant inheritance pattern."
    explanation: >-
      Recorded as REFUTE because this sentence contradicts the recessive
      inheritance every reported case supports, including this report's own
      homozygous proband with related parents. Curated rather than omitted so a
      later curator does not read the claim as unexamined.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Reported cases are counted in families rather than in rates. Five patients
    from three families were known by 2022; the two sisters reported that year,
    an adolescent girl in 2024 and a woman with a ligand-binding-domain variant
    in 2025 bring the cited total to six families. No population estimate
    exists.
  evidence:
  - reference: PMID:35134944
    reference_title: "Estrogen Receptor α Inactivation in 2 Sisters: Different Phenotypic Severities for the Same Pathogenic Variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Only 3 females and 2 males, from 3 families, with a loss of ERα function have been reported to date."
    explanation: A literature count at the time of the fourth family's report.
progression:
- phase: Onset
  age_range: Adolescence to young adulthood
  notes: >-
    Females present with absent pubertal breast development and primary
    amenorrhea in adolescence; the index male, normally masculinized, was
    recognised at 28 years from continued linear growth and open epiphyses.
  evidence:
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We now describe an 18-year-old woman without breast development and with markedly elevated serum levels of estrogens and bilateral multicystic ovaries."
    explanation: Adolescent presentation with failed pubertal development in a female.
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 28-year-old man whose estrogen resistance was caused by a disruptive mutation in the estrogen-receptor gene underwent studies of pituitary-gonadal function and bone density and received transdermal estrogen for six months."
    explanation: The index male was identified in adulthood.
- phase: Course
  age_range: Adulthood
  notes: >-
    Linear growth continues into the third decade and bone mineral density falls
    further despite estrogen or selective estrogen receptor modulator treatment.
  evidence:
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient presented a continuous linear growth (height + 3SD at the age of 28.6 years)."
    explanation: Eight-year follow-up documents ongoing growth into the late twenties.
  - reference: PMID:18505767
    reference_title: "Impact on bone of an estrogen receptor-alpha gene loss of function mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spine aBMD at age 28.5 yr (0.745 g/cm(2)) decreased to 0.684 g/cm(2) (Z score -3.85) in 3.5 yr."
    explanation: Longitudinal bone loss in the index male over three and a half years.
pathophysiology:
- name: ESR1 Loss-of-Function
  biological_scale: MOLECULAR
  description: >-
    Homozygous ESR1 variants abolish or severely reduce the transcriptional
    activity of estrogen receptor alpha. The index variant is a premature stop
    codon at codon 157 that truncates the receptor; the later missense variants
    (Q375H, E385V, R394H, M543T) sit in the ligand-binding domain and impair
    ligand anchoring, coactivator recruitment or nuclear translocation, so the
    receptor is present but cannot drive estrogen-responsive transcription.
  genes:
  - preferred_term: ESR1
    description: >-
      The gene encoding estrogen receptor alpha, the nuclear receptor whose
      biallelic loss defines the disease.
    term:
      id: hgnc:3467
      label: ESR1
  genetic_context:
    variant_origin: GERMLINE
    zygosity: HOMOZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
  molecular_functions:
  - preferred_term: nuclear estrogen receptor activity
    modifier: LOSS_OF_FUNCTION
    description: >-
      The receptor cannot transduce estradiol into transcriptional output. This
      is a qualitative loss in the receptor's own function rather than a lower
      level of a regulated activity, hence LOSS_OF_FUNCTION rather than
      DECREASED.
    term:
      id: GO:0030284
      label: nuclear estrogen receptor activity
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Direct sequencing of exon 2 revealed a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a premature stop codon."
    explanation: The index lesion, a biallelic truncating variant in the receptor gene.
  - reference: PMID:27754803
    reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Structural and functional analysis of the mutant ERα revealed strongly reduced transcriptional activity and the inability to securely anchor the activating hormone, estradiol, compared with wild-type ERα."
    explanation: Functional assay of the R394H receptor showing loss of transcriptional activity and of stable ligand anchoring.
  - reference: PMID:32963012
    reference_title: "A mutant form of ERα associated with estrogen insensitivity affects the coupling between ligand binding and coactivator recruitment."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The identity of residue 375 greatly affected the sensitivity of the receptor to agonists without changing the ligand binding affinity."
    explanation: The Q375H receptor binds ligand normally but fails to couple binding to coactivator recruitment, a second molecular route to the same loss of function.
  - reference: PMID:35134944
    reference_title: "Estrogen Receptor α Inactivation in 2 Sisters: Different Phenotypic Severities for the Same Pathogenic Variant."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The transient expression of ERα-E385V in HEK293A and MDA-MB231 cells revealed highly impaired ERE-dependent transcriptional activation by E2."
    explanation: A third variant, E385V, with impaired estrogen-response-element transcription in cell assays.
  downstream:
  - target: Loss of Estrogen Receptor Signaling in Target Tissues
    causal_link_type: DIRECT
    description: >-
      A receptor that cannot drive estrogen-responsive transcription leaves
      every estrogen-dependent tissue unresponsive to circulating estradiol.
    evidence:
    - reference: PMID:32242619
      reference_title: "ESR1 Mutations Associated With Estrogen Insensitivity Syndrome Change Conformation of Ligand-Receptor Complex and Altered Transcriptome Profile."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Comparison of the transcriptome and deoxyribonucleic acid methylome from stable cell lines of both Q375H and R394H clinical mutants shows a differential profile compared with wild-type ERα, resulting in loss of estrogen responsiveness."
      explanation: Links the two patient variants to loss of the estrogen-responsive transcriptome.
- name: Loss of Estrogen Receptor Signaling in Target Tissues
  biological_scale: CELLULAR
  description: >-
    Cells in bone, the reproductive tract, the hypothalamic-pituitary axis and
    metabolic tissues receive abundant estradiol but mount no transcriptional
    response to it. The state is the mirror image of aromatase deficiency: the
    ligand is present in excess and the response is absent.
  biological_processes:
  - preferred_term: estrogen receptor signaling pathway
    modifier: DECREASED
    description: >-
      DECREASED rather than ABSENT because the hypomorphic ligand-binding-domain
      alleles retain measurable signalling at supraphysiological estradiol: the
      Q375H receptor's half-maximal concentration is 240-fold that of the
      wild-type receptor rather than unattainable, and a partially compensating
      route is invoked for the E385V sisters.
    term:
      id: GO:0030520
      label: estrogen receptor signaling pathway
  - preferred_term: cellular response to estradiol stimulus
    modifier: DECREASED
    term:
      id: GO:0071392
      label: cellular response to estradiol stimulus
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient had no detectable response to estrogen administration, despite a 10-fold increase in the serum free estradiol concentration."
    explanation: Direct clinical demonstration that target tissues do not respond to estrogen even at supraphysiological exposure.
  - reference: PMID:42734155
    reference_title: "Estrogen insensitivity syndrome: the 'Upside Down' of ESR1 mutations."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "In contrast, germline ESR1 mutations cause EIS by impairing ERα function and rendering peripheral tissues insensitive to circulating E2."
    explanation: Review statement of the tissue-level consequence of germline receptor loss, contrasted with somatic activating mutations in breast cancer.
  downstream:
  - target: Loss of Estrogen Negative Feedback on the Gonadotropin Axis
    causal_link_type: DIRECT
    description: >-
      Hypothalamic and pituitary cells cannot register estradiol, so the
      negative feedback that normally restrains gonadotropin release is lost.
  - target: Failure of Epiphyseal Fusion
    causal_link_type: DIRECT
    description: >-
      Growth plate cells cannot execute the estrogen-dependent program of
      pubertal maturation and epiphyseal fusion.
  - target: Increased Bone Resorption with Failed Mineral Accrual
    causal_link_type: DIRECT
    description: >-
      Bone cells lose the estrogen restraint on resorption and the support for
      mineral accrual.
  - target: Failure of Estrogen-Dependent Female Reproductive Development
    causal_link_type: DIRECT
    description: >-
      Mammary, uterine and ovarian tissue cannot respond to the estradiol that
      would normally drive pubertal development.
  - target: Insulin Resistance and Metabolic Dysregulation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Loss of estrogen receptor alpha action in metabolic tissues is followed by
      impaired glucose tolerance and hyperinsulinemia in some patients. The path
      is not established: the phenotype is absent in at least one proband, and
      exogenous estrogen improves insulin sensitivity in a patient whose
      skeleton does not respond, so a residual estrogen-responsive route in
      metabolic tissue is likely and unmapped.
- name: Loss of Estrogen Negative Feedback on the Gonadotropin Axis
  biological_scale: ORGANISM
  description: >-
    Without receptor-mediated estrogen feedback, follicle-stimulating and
    luteinizing hormone secretion is disinhibited. Gonadotropins rise, the
    gonads are driven to produce estradiol, and estradiol accumulates to many
    times the normal range because nothing downstream registers it. In females
    the sustained gonadotropin drive produces enlarged multicystic ovaries.
  biological_processes:
  - preferred_term: negative regulation of gonadotropin secretion
    modifier: ABSENT
    term:
      id: GO:0032277
      label: negative regulation of gonadotropin secretion
  - preferred_term: gonadotropin secretion
    modifier: INCREASED
    term:
      id: GO:0032274
      label: gonadotropin secretion
  chemical_entities:
  - preferred_term: estradiol
    modifier: INCREASED
    term:
      id: CHEBI:23965
      label: estradiol
  locations:
  - preferred_term: hypothalamus
    term:
      id: UBERON:0001898
      label: hypothalamus
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serum estradiol and estrone concentrations were elevated, and serum testosterone concentrations were normal. Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
    explanation: The defining endocrine signature in the index male, high estrogens with high gonadotropins and normal testosterone.
  - reference: PMID:27754803
    reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
    explanation: Quantifies the estradiol and gonadotropin elevation across three siblings.
  - reference: PMID:32152632
    reference_title: "Long-Term Follow-Up and Treatment of a Female With Complete Estrogen Insensitivity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Luteinizing hormone (LH) pulse studies demonstrated normal pulsatile LH secretion, elevated mean LH, and mildly elevated mean follicle-stimulating hormone (FSH) in the presence of markedly increased estrogens."
    explanation: Pulse studies show the axis is intact in pattern and raised in level, which is what loss of feedback rather than a hypothalamic lesion predicts.
  downstream:
  - target: Elevated circulating follicle stimulating hormone level
    description: Disinhibited FSH secretion.
  - target: Elevated circulating luteinizing hormone level
    description: Disinhibited LH secretion.
  - target: Increased serum estradiol
    description: Gonadotropin-driven estradiol production that nothing downstream registers.
  - target: Enlarged polycystic ovaries
    causal_link_type: DIRECT
    description: >-
      Unrestrained gonadotropin stimulation of ovaries that cannot respond to
      their own estradiol produces enlarged multicystic ovaries. This is the
      ovarian arm, distinct from the receptor's direct failure in breast and
      uterus, which reaches those tissues without passing through the
      gonadotropin axis.
    evidence:
    - reference: PMID:27754803
      reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The 2 sisters had enlarged multicystic ovaries."
      explanation: >-
        The ovarian phenotype in the two sisters whose gonadotropins the same
        report puts above threefold the normal range, which is the drive this
        edge carries.
    - reference: PMID:8248223
      reference_title: "Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: "Females have hypoplastic uteri and hyperemic ovaries with no detectable corpora lutea."
      explanation: The receptor-null mouse reproduces the ovarian consequence; graded INDIRECT because it is the mouse orthologue rather than a patient observation.
- name: Failure of Epiphyseal Fusion
  biological_scale: TISSUE
  description: >-
    Estrogen acting through estrogen receptor alpha drives growth plate
    maturation and epiphyseal fusion at puberty. Without receptor signalling
    bone age lags chronological age by years and the epiphyses stay open, so
    linear growth continues into adulthood in most reported patients. The
    pubertal growth spurt itself is estrogen-driven and is absent, which is why
    continued growth does not always produce tall stature.
  cell_types:
  - preferred_term: growth plate chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: growth plate cartilage development
    modifier: ABNORMAL
    term:
      id: GO:0003417
      label: growth plate cartilage development
  locations:
  - preferred_term: epiphyseal plate
    term:
      id: UBERON:0002516
      label: epiphyseal plate
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "had incomplete epiphyseal closure, with a history of continued linear growth into adulthood despite otherwise normal pubertal development."
    explanation: Open epiphyses and continued growth in an adult male with the receptor lesion.
  - reference: PMID:9554463
    reference_title: "Pediatric endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: "However, they lead to absence of the pubertal growth spurt, delayed bone maturation, unfused epiphyses, continued growth into adulthood and very tall adult stature in both sexes."
    explanation: >-
      Review synthesis of the growth-plate consequence shared by estrogen
      resistance and aromatase deficiency, which places the lesion in estrogen
      action on the epiphysis.
  - reference: PMID:18505767
    reference_title: "Impact on bone of an estrogen receptor-alpha gene loss of function mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone age advanced from 15-17.5 yr."
    explanation: >-
      Bone age in the index male remained in the mid-teens across a follow-up
      spanning his late twenties to early thirties.
  downstream:
  - target: Tall stature
    description: Continued linear growth from unfused epiphyses in most reported patients.
  - target: Delayed skeletal maturation
    description: Bone age lags chronological age by years.
  - target: Absent pubertal growth spurt
    description: The estrogen-driven pubertal acceleration of growth velocity does not occur.
- name: Increased Bone Resorption with Failed Mineral Accrual
  biological_scale: TISSUE
  description: >-
    Estrogen receptor alpha signalling restrains osteoclastic resorption and
    supports mineral accrual. Without it, trabecular and cortical bone are
    markedly undermineralized with a high-turnover signature on biopsy and
    raised turnover markers, and bone density continues to fall in adulthood
    despite estrogen or selective estrogen receptor modulator treatment.
    Periosteal circumference is spared.
  cell_types:
  - preferred_term: osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  biological_processes:
  - preferred_term: bone resorption
    modifier: INCREASED
    term:
      id: GO:0045453
      label: bone resorption
  - preferred_term: bone mineralization
    modifier: DECREASED
    term:
      id: GO:0030282
      label: bone mineralization
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The bone mineral density of the lumbar spine was 0.745 g per square centimeter, 3.1 SD below the mean for age-matched normal women; there was biochemical evidence of increased bone turnover."
    explanation: Undermineralized bone with a high-turnover signature.
  - reference: PMID:18505767
    reference_title: "Impact on bone of an estrogen receptor-alpha gene loss of function mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Homozygous ER-alpha disruption markedly affects bone growth, mineral content, and structure but not periosteal circumference."
    explanation: >-
      Bone biopsy and quantitative computed tomography of the index case define
      the skeletal lesion and its one spared compartment.
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Markers of bone turnover were increased and unresponsive to treatment."
    explanation: >-
      The same high-turnover skeletal state in a female with a
      ligand-binding-domain variant, unchanged by estrogen or tamoxifen.
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Levels of both osteocalcin and C-telopeptide were elevated, suggesting increased bone turnover.
    explanation: >-
      Bone formation and resorption markers both elevated in the Q375H proband,
      which is the biochemical form of the high-turnover state this node names.
  downstream:
  - target: Osteoporosis
    description: Undermineralized, high-turnover bone.
- name: Failure of Estrogen-Dependent Female Reproductive Development
  biological_scale: TISSUE
  description: >-
    Breast development and uterine growth at puberty require estrogen receptor
    alpha, so affected females have no breast development, a small uterus and
    primary amenorrhea despite very high estradiol. This node is the receptor's
    direct failure in those target tissues. The ovarian enlargement of this
    disease is a separate mechanism and hangs off the gonadotropin-feedback
    node instead, because it is driven by unopposed gonadotropins rather than
    by the missing estrogen signal in the ovary.
  biological_processes:
  - preferred_term: mammary gland development
    modifier: ABSENT
    term:
      id: GO:0030879
      label: mammary gland development
  locations:
  - preferred_term: mammary gland
    term:
      id: UBERON:0001911
      label: mammary gland
  - preferred_term: uterus
    term:
      id: UBERON:0000995
      label: uterus
  evidence:
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This case shows that disruption of ESR1 causes profound estrogen resistance in women."
    explanation: The first female case establishes the reproductive phenotype as a consequence of ESR1 disruption.
  - reference: PMID:39295121
    reference_title: "Estrogen-insensitivity syndrome (EIS) in a female adolescent patient - a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, the case of a 13-year-old girl, with high estrogen and gonadotropin concentrations, lack of breast development, uterine growth and delayed bone age is described."
    explanation: >-
      Breast and uterine failure together in one patient, which is the pair of
      target tissues this node is now scoped to.
  downstream:
  - target: Breast aplasia
    description: No pubertal breast development despite high estradiol.
  - target: Primary amenorrhea
    description: No menarche.
  - target: Hypoplasia of the uterus
    description: Loss of the estrogen drive on uterine growth.
  - target: Delayed puberty
    description: Failure to enter estrogen-dependent puberty in females.
- name: Insulin Resistance and Metabolic Dysregulation
  biological_scale: ORGANISM
  description: >-
    Loss of estrogen receptor alpha action is accompanied by impaired glucose
    tolerance, hyperinsulinemia, reduced insulin sensitivity, raised leptin and
    axillary acanthosis nigricans. Exogenous ethinyl-estradiol improved insulin
    sensitivity in one long-term follow-up even though it did not help bone,
    suggesting a residual estrogen-responsive route in metabolic tissue that is
    absent in the skeleton.
  biological_processes:
  - preferred_term: cellular response to insulin stimulus
    modifier: DECREASED
    term:
      id: GO:0032869
      label: cellular response to insulin stimulus
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Glucose tolerance was impaired, and hyperinsulinemia was present."
    explanation: The metabolic phenotype in the index case.
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The metabolic phenotype included insulin resistance, decreased insulin sensitivity and increased leptinemia."
    explanation: The same metabolic picture in a female case with eight years of follow-up.
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our patient had normal levels of fasting glucose, insulin, and glycated hemoglobin and a normal HOMA-IR, indicating no impaired glucose tolerance.
    explanation: >-
      Refutes the metabolic phenotype as a constant feature. The Q375H proband
      had normal fasting glucose, insulin, glycated hemoglobin and insulin
      resistance index, which is why the node and the entry description report
      it in some patients rather than all.
  - reference: PMID:9554463
    reference_title: "Pediatric endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: "Glucose intolerance, hyperinsulinemia and lipid abnormalities are also present."
    explanation: Review synthesis placing the metabolic phenotype alongside the skeletal one in estrogen resistance and aromatase deficiency.
  downstream:
  - target: Impaired glucose tolerance
    description: Reduced insulin action on glucose disposal.
  - target: Hyperinsulinemia
    description: Compensatory insulin excess.
  - target: Acanthosis nigricans
    description: Cutaneous marker of hyperinsulinemia.
phenotypes:
- name: Tall stature
  category: Skeletal
  description: >-
    Height above +2 SD from continued linear growth through unfused epiphyses in
    most reported patients; the index male measured 204 cm and a female case
    reached +3 SD at 28 years. It is not invariable: the Q375H proband lacked
    the pubertal growth spurt and stayed below the 50th height percentile.
  phenotype_term:
    preferred_term: Tall stature
    term:
      id: HP:0000098
      label: Tall stature
  evidence:
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient, first seen at the age of 21.3 years, presented with a tall stature (+2.2 SD), a delayed bone age (13 years)."
    explanation: Tall stature with delayed bone age in a female case.
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient was tall (204 cm"
    explanation: >-
      The height of the index male, which the description quotes. Truncated
      before the parenthetical imperial conversion, since bracketed spans are
      stripped before snippet matching.
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Her growth velocity indicated the lack of an estrogen-induced growth spurt at the time of puberty
    explanation: >-
      Refutes tall stature as a constant feature. This proband had no
      estrogen-driven pubertal acceleration and remained below the 50th height
      percentile, which is why the description reports tall stature in most
      patients rather than all.
- name: Absent pubertal growth spurt
  category: Skeletal
  description: >-
    The estrogen-driven acceleration of growth velocity at puberty does not
    occur, which is why continued growth from unfused epiphyses does not always
    produce tall stature.
  phenotype_term:
    preferred_term: Absent pubertal growth spurt
    term:
      id: HP:0031087
      label: Absent pubertal growth spurt
  evidence:
  - reference: PMID:9554463
    reference_title: "Pediatric endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: "However, they lead to absence of the pubertal growth spurt, delayed bone maturation, unfused epiphyses, continued growth into adulthood and very tall adult stature in both sexes."
    explanation: Review synthesis naming the absent growth spurt in both estrogen resistance and aromatase deficiency.
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Her growth velocity indicated the lack of an estrogen-induced growth spurt at the time of puberty
    explanation: Growth velocity in the Q375H proband shows the missing estrogen-driven spurt.
- name: Delayed skeletal maturation
  category: Skeletal
  description: >-
    Bone age lags chronological age by many years, with persistence of open
    epiphyses into adulthood.
  phenotype_term:
    preferred_term: Delayed bone age with persistently open epiphyses
    term:
      id: HP:0002750
      label: Delayed skeletal maturation
  evidence:
  - reference: PMID:27754803
    reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An ESR1 mutation was identified in 2 sisters and 1 brother, originating from a consanguineous Algerian family, who did not enter puberty and presented with delayed bone maturation consistent with estrogen insensitivity."
    explanation: Delayed bone maturation in all three affected siblings.
  - reference: PMID:18505767
    reference_title: "Impact on bone of an estrogen receptor-alpha gene loss of function mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone age advanced from 15-17.5 yr."
    explanation: Bone age in the index male remained in the mid-teens across a follow-up spanning his late twenties to early thirties.
- name: Osteoporosis
  category: Skeletal
  description: >-
    Lumbar spine bone mineral density three to five standard deviations below
    the mean, worsening over time and unresponsive to estrogen or tamoxifen.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She had a severe osteoporosis of the lumbar spine (Z-score -3.9) and osteopenia of the femoral neck (Z-score -1.8)."
    explanation: Densitometric osteoporosis in a female case.
  - reference: PMID:18505767
    reference_title: "Impact on bone of an estrogen receptor-alpha gene loss of function mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone biopsy revealed marked osteopenia (cortex: 641 microm), low trabecular volume (10.6%), decreased thickness (76.2 microm), normal trabecular number, and low activation frequency (0.099/yr)."
    explanation: Histomorphometric confirmation in the index male.
- name: Breast aplasia
  category: Reproductive
  description: >-
    Absent pubertal breast development in affected females despite markedly
    elevated estradiol.
  phenotype_term:
    preferred_term: Absent breast development
    term:
      id: HP:0100783
      label: Breast aplasia
  evidence:
  - reference: PMID:35134944
    reference_title: "Estrogen Receptor α Inactivation in 2 Sisters: Different Phenotypic Severities for the Same Pathogenic Variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 36-year-old woman from a consanguineous Jordanian family presented with primary amenorrhea and no breast development, with high plasma levels of 17β-estradiol (E2), follicle-stimulating hormone and luteinizing hormone, and enlarged multifollicular ovaries, strongly suggesting estrogen resistance."
    explanation: Absent breast development together with the defining hormonal picture.
- name: Primary amenorrhea
  category: Reproductive
  description: Absence of menarche in affected females.
  phenotype_term:
    preferred_term: Primary amenorrhea
    term:
      id: HP:0000786
      label: Primary amenorrhea
  evidence:
  - reference: PMID:35134944
    reference_title: "Estrogen Receptor α Inactivation in 2 Sisters: Different Phenotypic Severities for the Same Pathogenic Variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 36-year-old woman from a consanguineous Jordanian family presented with primary amenorrhea and no breast development, with high plasma levels of 17β-estradiol (E2), follicle-stimulating hormone and luteinizing hormone, and enlarged multifollicular ovaries, strongly suggesting estrogen resistance."
    explanation: Primary amenorrhea in an adult female case.
- name: Hypoplasia of the uterus
  category: Reproductive
  description: >-
    A small uterus with no clearly identifiable endometrial stripe, from loss of
    the estrogen drive on uterine growth.
  phenotype_term:
    preferred_term: Small uterus
    term:
      id: HP:0000013
      label: Hypoplasia of the uterus
  evidence:
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ultrasonography revealed a small uterus with no clearly identifiable endometrial stripe and markedly enlarged multicystic ovaries
    explanation: Imaging of the uterus and ovaries in the first female case.
- name: Enlarged polycystic ovaries
  category: Reproductive
  description: >-
    Bilateral enlarged multicystic or multifollicular ovaries under sustained
    gonadotropin drive; present in most but not all affected females.
  phenotype_term:
    preferred_term: Enlarged multicystic ovaries
    term:
      id: HP:0008675
      label: Enlarged polycystic ovaries
  evidence:
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We now describe an 18-year-old woman without breast development and with markedly elevated serum levels of estrogens and bilateral multicystic ovaries."
    explanation: Bilateral multicystic ovaries in the first female case.
  - reference: PMID:27754803
    reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The 2 sisters had enlarged multicystic ovaries."
    explanation: Enlarged multicystic ovaries in two further females.
- name: Delayed puberty
  category: Reproductive
  description: >-
    Failure to enter estrogen-dependent puberty in females; the index male had
    otherwise normal pubertal development, so the feature is female-restricted
    in the cases reported so far.
  phenotype_term:
    preferred_term: Delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  evidence:
  - reference: PMID:35134944
    reference_title: "Estrogen Receptor α Inactivation in 2 Sisters: Different Phenotypic Severities for the Same Pathogenic Variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her 18-year-old sister did not enter puberty and had moderately high levels of E2, high plasma gonadotropin levels, and normal ovaries."
    explanation: Absent puberty in an affected female.
- name: Elevated circulating follicle stimulating hormone level
  category: Endocrine
  description: FSH above the normal range from loss of estrogen negative feedback.
  phenotype_term:
    preferred_term: Elevated FSH
    term:
      id: HP:0008232
      label: Elevated circulating follicle stimulating hormone level
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
    explanation: Elevated gonadotropins in the index male.
- name: Elevated circulating luteinizing hormone level
  category: Endocrine
  description: LH above the normal range from loss of estrogen negative feedback.
  phenotype_term:
    preferred_term: Elevated LH
    term:
      id: HP:0011969
      label: Elevated circulating luteinizing hormone level
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
    explanation: Elevated gonadotropins in the index male.
- name: Increased serum estradiol
  category: Endocrine
  description: >-
    Estradiol many times the normal range, up to more than fifty-fold, because
    the gonads are driven by unrestrained gonadotropins and nothing downstream
    registers the hormone.
  phenotype_term:
    preferred_term: Markedly elevated serum estradiol
    term:
      id: HP:0025134
      label: Increased serum estradiol
  evidence:
  - reference: PMID:27754803
    reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
    explanation: Quantified estradiol elevation across three siblings.
- name: Impaired glucose tolerance
  category: Metabolic
  description: Impaired glucose tolerance with hyperinsulinemia in the index male.
  phenotype_term:
    preferred_term: Impaired glucose tolerance
    term:
      id: HP:0040270
      label: Impaired glucose tolerance
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Glucose tolerance was impaired, and hyperinsulinemia was present."
    explanation: Impaired glucose tolerance in the index case.
- name: Hyperinsulinemia
  category: Metabolic
  description: Compensatory hyperinsulinemia with insulin resistance.
  phenotype_term:
    preferred_term: Hyperinsulinemia
    term:
      id: HP:0000842
      label: Hyperinsulinemia
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Glucose tolerance was impaired, and hyperinsulinemia was present."
    explanation: Hyperinsulinemia in the index case.
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The metabolic phenotype included insulin resistance, decreased insulin sensitivity and increased leptinemia."
    explanation: Insulin resistance in a female case.
- name: Acanthosis nigricans
  category: Dermatological
  description: Bilateral axillary acanthosis nigricans, the cutaneous marker of hyperinsulinemia, in both sexes.
  phenotype_term:
    preferred_term: Axillary acanthosis nigricans
    term:
      id: HP:0000956
      label: Acanthosis nigricans
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He was normally masculinized and had bilateral axillary acanthosis nigricans."
    explanation: Acanthosis nigricans in the index male.
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She had no breast development, normal axillary and pubic pilosity and bilateral axillary acanthosis nigricans."
    explanation: The same finding in a female case.
genetic:
- name: ESR1
  gene_term:
    preferred_term: ESR1
    term:
      id: hgnc:3467
      label: ESR1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    Every reported case is homozygous. Variants: p.Arg157Ter (the 1994 index
    male), p.Gln375His (the first female, 2013), p.Arg394His (three Algerian
    siblings, 2017), p.Glu385Val (two Jordanian sisters, 2022), p.Met543Thr (a
    2025 case report) and an unspecified homozygous variant in a 13-year-old
    girl reported in 2024 (PMID:39295121). That report's abstract calls the
    syndrome autosomal dominant, which contradicts its own homozygous finding
    and related parents, and is not followed here. A heterozygous p.Ala207Thr
    variant reported in a woman
    with polycystic ovary syndrome and a poor gonadotropin response during IVF
    (PMID:36401248) is not counted here: it is heterozygous, functionally
    untested and in a patient with a different diagnosis.
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Direct sequencing of exon 2 revealed a cytosine-to-thymine transition at codon 157 of both alleles, resulting in a premature stop codon."
    explanation: The index biallelic truncating variant.
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She was found to have a homozygous loss-of-function ESR1 mutation in a completely conserved residue that interferes with estrogen signaling."
    explanation: The first female case, homozygous for a missense variant.
  - reference: PMID:39295121
    reference_title: "Estrogen-insensitivity syndrome (EIS) in a female adolescent patient - a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She was found to have a homozygous pathogenic variant in the ESR1 gene located on chromosome 6q25, which interferes with estrogen signaling."
    explanation: >-
      The sixth reported family, homozygous at the ESR1 locus. Cited for the
      variant and the locus only; this report's abstract also calls the
      syndrome autosomal dominant, which its own homozygous finding and
      related parents contradict, so it is not used for inheritance.
biochemical:
- name: Serum Estradiol
  presence: INCREASED
  context: >-
    Estradiol is markedly elevated, up to more than fifty-fold the normal range,
    because gonadotropin drive is unrestrained and the hormone is not registered
    by its receptor.
  biomarker_term:
    preferred_term: estradiol
    term:
      id: CHEBI:23965
      label: estradiol
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serum estradiol and estrone concentrations were elevated, and serum testosterone concentrations were normal."
    explanation: Elevated estradiol in the index case.
  readouts:
  - target: Loss of Estrogen Negative Feedback on the Gonadotropin Axis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: High estradiol with high gonadotropins distinguishes receptor resistance from aromatase deficiency, where estradiol is low.
    evidence:
    - reference: PMID:27754803
      reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
      explanation: The authors read the combination as the diagnostic signature of estrogen resistance.
- name: Estrogen-Regulated Hepatic Binding Proteins
  presence: NORMAL
  context: >-
    Corticosteroid-binding, sex-hormone-binding and thyroxine-binding globulins
    are not raised despite markedly elevated estrogen, which is the hepatic
    readout of the resistance itself: in any state of true estrogen excess these
    proteins rise.
  readouts:
  - target: Loss of Estrogen Receptor Signaling in Target Tissues
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Unchanged estrogen-regulated hepatic proteins in the presence of high
      estradiol report that the hormone is not being transduced.
    evidence:
    - reference: PMID:23841731
      reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Serum levels of corticosteroid-binding globulin, sex-hormone–binding globulin, thyroxine-binding globulin, prolactin, and triglycerides were not increased, despite elevated estrogen levels.
      explanation: >-
        The measurement behind this readout, and the cleanest biochemical
        demonstration that target tissues do not register the circulating
        hormone.
- name: Serum Follicle-Stimulating Hormone
  presence: INCREASED
  context: FSH is elevated from loss of estrogen negative feedback.
  biomarker_term:
    preferred_term: follicle stimulating hormone
    term:
      id: CHEBI:81569
      label: Follicle stimulating hormone
  evidence:
  - reference: PMID:27754803
    reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
    explanation: Gonadotropins above threefold the normal range across three siblings.
  readouts:
  - target: Loss of Estrogen Negative Feedback on the Gonadotropin Axis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated FSH reports the disinhibited gonadotropin axis.
    evidence:
    - reference: PMID:8090165
      reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
      explanation: Elevated FSH in the index case.
- name: Serum Luteinizing Hormone
  presence: INCREASED
  context: LH is elevated from loss of estrogen negative feedback.
  biomarker_term:
    preferred_term: luteinizing hormone
    term:
      id: CHEBI:81568
      label: Luteinizing hormone
  evidence:
  - reference: PMID:35134944
    reference_title: "Estrogen Receptor α Inactivation in 2 Sisters: Different Phenotypic Severities for the Same Pathogenic Variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her 18-year-old sister did not enter puberty and had moderately high levels of E2, high plasma gonadotropin levels, and normal ovaries."
    explanation: High gonadotropins even in the milder sister.
  readouts:
  - target: Loss of Estrogen Negative Feedback on the Gonadotropin Axis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated LH reports the disinhibited gonadotropin axis.
    evidence:
    - reference: PMID:8090165
      reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Serum follicle-stimulating hormone and luteinizing hormone concentrations were increased."
      explanation: Elevated LH in the index case.
animal_models:
- name: Estrogen receptor-null mouse (alphaERKO, insertional disruption of Esr1)
  species: Mouse
  genotype: Esr1 insertional disruption, homozygous
  publication: PMID:8248223
  description: >-
    The first receptor-null mouse. Both sexes survive with normal external
    phenotypes; females are infertile with hypoplastic uteri and hyperemic
    ovaries lacking corpora lutea, and their uteri do not respond to estradiol.
  evidence:
  - reference: PMID:8248223
    reference_title: "Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Both male and female animals survive to adulthood with normal gross external phenotypes. Females are infertile; males have a decreased fertility."
    explanation: Viability and the reproductive phenotype of the receptor-null mouse.
  modeled_mechanisms:
  - target: Loss of Estrogen Receptor Signaling in Target Tissues
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: ORGANISM
    description: >-
      Complete receptor loss with preserved viability and an unresponsive
      reproductive tract, the state the human disease was later shown to share.
    limitations: >-
      Insertional disruption rather than a patient variant; the mouse lacks the
      continued longitudinal growth of humans with open epiphyses, since rodent
      growth plates do not fuse.
    evidence:
    - reference: PMID:8248223
      reference_title: "Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We have generated mutant mice lacking responsiveness to estradiol by disrupting the estrogen receptor gene by gene targeting."
      explanation: The model is defined by loss of estradiol responsiveness, which is the node's claim.
    readouts:
    - name: Uterine wet weight response to estradiol
      target: Loss of Estrogen Receptor Signaling in Target Tissues
      direction: ABOLISHED
      interpretation: Tissue-level estrogen responsiveness is absent in the receptor-null animal.
      evidence:
      - reference: PMID:8248223
        reference_title: "Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "In adult wild-type and heterozygous females, 3-day estradiol treatment at 40 micrograms/kg stimulates a 3- to 4-fold increase in uterine wet weight and alters vaginal cornification, but the uteri and vagina do not respond in the animals with the estrogen receptor gene disruption."
        explanation: The measurement behind the readout.
- name: Esr1-Q375H knock-in mouse (patient variant)
  species: Mouse
  genotype: Esr1 p.Gln375His homozygous, CRISPR/Cas9 knock-in
  publication: PMID:32242619
  description: >-
    A mouse carrying the human Q375H variant. Both sexes are infertile with
    phenotypes resembling the receptor-null mouse and corresponding to the
    patient the variant came from.
  evidence:
  - reference: PMID:32242619
    reference_title: "ESR1 Mutations Associated With Estrogen Insensitivity Syndrome Change Conformation of Ligand-Receptor Complex and Altered Transcriptome Profile."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Furthermore, we generated a mouse model Esr1-Q harboring the human mutation using CRISPR/Cas9 genome editing."
    explanation: The model's construction from the patient variant.
  modeled_mechanisms:
  - target: ESR1 Loss-of-Function
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: ORGANISM
    description: >-
      The patient's own missense variant reproduces receptor loss of function in
      vivo rather than by gene deletion.
    limitations: >-
      Reported phenotypes are reproductive; skeletal and metabolic features of
      the human disease are not described in the abstract.
    evidence:
    - reference: PMID:32242619
      reference_title: "ESR1 Mutations Associated With Estrogen Insensitivity Syndrome Change Conformation of Ligand-Receptor Complex and Altered Transcriptome Profile."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Female and male Esr1-Q mice are infertile and have similar phenotypes to αERKO mice."
      explanation: The knock-in phenocopies the receptor-null animal.
    readouts:
    - name: Fertility of homozygous Q375H knock-in mice
      target: ESR1 Loss-of-Function
      direction: ABOLISHED
      interpretation: >-
        Both sexes are infertile, the same outcome as receptor deletion, which
        is what marks the patient's missense allele as a loss of function in
        vivo.
      evidence:
      - reference: PMID:32242619
        reference_title: "ESR1 Mutations Associated With Estrogen Insensitivity Syndrome Change Conformation of Ligand-Receptor Complex and Altered Transcriptome Profile."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Female and male Esr1-Q mice are infertile and have similar phenotypes to αERKO mice."
        explanation: The measured outcome behind this readout.
treatments:
- name: Estrogen Administration
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Estrogen given to test or overcome the resistance. Transdermal estradiol
    for six months produced no detectable response in the index male, and
    ethinyl-estradiol followed by tamoxifen did not arrest bone loss in a
    female followed for eight years. Ethinyl-estradiol did improve insulin
    sensitivity, lower leptin and raise some estrogen-regulated liver proteins
    in that patient, so a partial metabolic benefit is documented while the
    skeletal phenotype is not treatable by this route. No effective therapy for
    the bone disease is known.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: estradiol
      term:
        id: CHEBI:23965
        label: estradiol
    - preferred_term: ethinylestradiol
      description: >-
        The agent used in the eight-year follow-up, where it improved insulin
        sensitivity without arresting bone loss.
      term:
        id: CHEBI:4903
        label: 17alpha-ethynylestradiol
    - preferred_term: diethylstilbestrol
      description: >-
        Tried for two and a half years in the first female case because it
        transactivated her variant receptor in vitro; it induced no secondary
        sexual characteristics.
      term:
        id: CHEBI:41922
        label: diethylstilbestrol
  target_mechanisms:
  - target: Insulin Resistance and Metabolic Dysregulation
    description: >-
      Ethinyl-estradiol improved insulin sensitivity and lowered leptin in one
      long-term follow-up.
    evidence:
    - reference: PMID:40032016
      reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Treatment with ethinyl-estradiol improved insulin sensitivity, lowered leptinemia, increased some estrogen-regulated liver proteins and the E2/T ratio."
      explanation: The one documented benefit of estrogen administration in this disease.
  evidence:
  - reference: PMID:8090165
    reference_title: "Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient had no detectable response to estrogen administration, despite a 10-fold increase in the serum free estradiol concentration."
    explanation: Refutes estrogen administration as a treatment of the resistance itself in the index case.
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Osteoporosis worsened (Z-score -5.6 at the lumbar spine; Z-score -4.4 at the femoral neck) despite successive treatments with ethinyl-estradiol and tamoxifen (selective estrogen modulator)."
    explanation: >-
      Refutes estrogen administration as treatment of the skeletal disease. The
      same sentence also refutes the selective estrogen receptor modulator
      given after it, which is recorded as its own treatment below.
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, there are no effective therapeutic options."
    explanation: States the therapeutic gap that this treatment record documents.
  - reference: PMID:32152632
    reference_title: "Long-Term Follow-Up and Treatment of a Female With Complete Estrogen Insensitivity."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: "DES transactivated the variant ESR1 in vitro."
    explanation: The rationale for the diethylstilbestrol trial, a ligand that activated the patient's variant receptor in a cell assay. Graded INDIRECT because in vitro transactivation is one inference step from a clinical response.
  - reference: PMID:32152632
    reference_title: "Long-Term Follow-Up and Treatment of a Female With Complete Estrogen Insensitivity."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "However, DES treatment did not induce secondary sexual characteristics in our patient."
    explanation: Refutes diethylstilbestrol as treatment even where the variant receptor is activatable in vitro.
  - reference: PMID:27754803
    reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: "A group of other potential ER activating ligands were tested, but none overcame the estrogen insensitivity in these patients."
    explanation: >-
      Refutes the wider strategy this treatment record tests, not just the two
      agents tried in patients. A panel of alternative receptor-activating
      ligands was screened against the R394H receptor and none restored
      signalling, so the failure is a property of the receptor rather than of
      the particular ligand chosen.
- name: Selective Estrogen Receptor Modulator Therapy
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Tamoxifen was given after ethinyl-estradiol failed in the eight-year
    follow-up, on the rationale that a modulator might engage a receptor that
    estradiol could not. Bone loss continued through it. Recorded separately
    from estrogen administration because a selective modulator is a different
    pharmacological class, not a dose of estrogen.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tamoxifen
      term:
        id: CHEBI:41774
        label: tamoxifen
  evidence:
  - reference: PMID:40032016
    reference_title: "Novel estrogen receptor-α gene inactivating missense variant in a woman: Therapeutic challenge and long-term follow-up data."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Osteoporosis worsened (Z-score -5.6 at the lumbar spine; Z-score -4.4 at the femoral neck) despite successive treatments with ethinyl-estradiol and tamoxifen (selective estrogen modulator)."
    explanation: >-
      Refutes the selective estrogen receptor modulator as treatment of the
      skeletal disease; bone density fell further while it was given.
- name: Progestin Suppression of Gonadotropin-Driven Ovarian Enlargement
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Norethisterone given to the first female case was temporally associated with
    falling estradiol and with reduction in ovarian volume and cyst number,
    which returned when it was stopped. The progesterone receptor is intact in
    this disease, so progestin feedback can restrain the gonadotropin drive that
    the absent estrogen feedback releases. This is the only reported
    intervention that changes a phenotype here, and it addresses the ovarian
    consequence rather than the receptor defect.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: norethisterone
      term:
        id: CHEBI:7627
        label: norethisterone
  target_mechanisms:
  - target: Loss of Estrogen Negative Feedback on the Gonadotropin Axis
    description: >-
      Progesterone-receptor-mediated negative feedback substitutes for the
      absent estrogen feedback and lowers the gonadotropin drive on the ovary.
    evidence:
    - reference: PMID:23841731
      reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In addition, the administration of norethindrone was temporally associated with reductions in ovarian volume and number of cysts, which suggests that negative feedback mediated by progesterone receptor was intact.
      explanation: >-
        The authors read the ovarian response as evidence that
        progesterone-receptor-mediated negative feedback was intact, which is
        the mechanism this treatment acts through.
  evidence:
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, the administration of norethindrone was temporally associated with reductions in ovarian volume and number of cysts, which suggests that negative feedback mediated by progesterone receptor was intact.
    explanation: >-
      A single-patient, uncontrolled observation with an on-and-off course,
      which is why the treatment is recorded as documented rather than
      established.
diagnosis:
- name: ESR1 Sequencing with the High-Estradiol, High-Gonadotropin Profile
  description: >-
    The biochemical signature is markedly elevated estradiol together with
    elevated gonadotropins, which separates receptor resistance from aromatase
    deficiency: in that disease the same high gonadotropins accompany low or
    undetectable estradiol. Estrogen-regulated hepatic binding proteins are not
    raised despite the high estradiol, which is the confirmatory sign that the
    hormone is not being transduced. Diagnosis is completed by ESR1 sequencing,
    which in every reported case shows a homozygous variant.
  presence: Positive in affected individuals
  evidence:
  - reference: PMID:27754803
    reference_title: "Familial Multiplicity of Estrogen Insensitivity Associated With a Loss-of-Function ESR1 Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hormonal evaluation revealed extremely high plasma 17β-estradiol (>50-fold normal range) associated with elevated gonadotropin levels (greater than threefold normal range), highly suggestive of estrogen resistance."
    explanation: >-
      The authors read this combination as the diagnostic signature of estrogen
      resistance, which is what this record is built on.
  - reference: PMID:23841731
    reference_title: "Delayed puberty and estrogen resistance in a woman with estrogen receptor α variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Serum levels of corticosteroid-binding globulin, sex-hormone–binding globulin, thyroxine-binding globulin, prolactin, and triglycerides were not increased, despite elevated estrogen levels.
    explanation: >-
      The confirmatory hepatic sign: in any state of true estrogen excess these
      proteins rise, so unchanged levels alongside high estradiol demonstrate
      that the hormone is not being transduced.
  - reference: PMID:39295121
    reference_title: "Estrogen-insensitivity syndrome (EIS) in a female adolescent patient - a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She was found to have a homozygous pathogenic variant in the ESR1 gene located on chromosome 6q25, which interferes with estrogen signaling."
    explanation: Genetic confirmation by ESR1 sequencing in a patient presenting with the profile above.
differential_diagnoses:
- name: Aromatase deficiency
  description: >-
    The ligand-supply counterpart: CYP19A1 loss leaves estradiol low or
    undetectable with high gonadotropins, and the skeletal phenotype of tall
    stature, open epiphyses and osteoporosis overlaps. Estradiol level
    separates the two, and estrogen replacement is effective in aromatase
    deficiency but not here.
  evidence:
  - reference: PMID:11305285
    reference_title: "Aromatase deficiency and estrogen resistance: from molecular genetics to clinic."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Thus far, one estrogen-resistant human, a man with a mutant estrogen receptor-alpha gene, has been described. His clinical presentation was similar to that of aromatase-deficient men."
    explanation: The clinical overlap that makes aromatase deficiency the principal differential.
  - reference: PMID:34538723
    reference_title: "Congenital disorders of estrogen biosynthesis and action."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: OTHER
    snippet: "Germline loss-of-function variants in ESR1, the gene encoding estrogen receptor α, are known to cause of estrogen insensitivity/resistance."
    explanation: Places the two diseases side by side as the biosynthesis and action arms of congenital estrogen disorders; the sentence is quoted as the source prints it.
  - reference: PMID:9554463
    reference_title: "Pediatric endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor."
    supports: SUPPORT
    quote_role: REVIEW_SYNTHESIS
    evidence_source: HUMAN_CLINICAL
    snippet: "Gonadotropin and androgen levels are elevated in patients with either estrogen deficiency (aromatase deficiency) or estrogen resistance (estrogen receptor mutation)."
    explanation: The shared gonadotropin elevation; estradiol, low in one and high in the other, is what separates them.
- name: ESR2-related estrogen resistance with ovarian dysgenesis
  description: >-
    A dominant-negative ESR2 variant produced complete lack of estrogen action
    with absent breast development, primary amenorrhea and osteoporosis, but
    with streak gonads, which ESR1-deficient patients do not have. It is a
    separate gene and a separate entity.
  evidence:
  - reference: PMID:30113650
    reference_title: "Early-Onset Complete Ovarian Failure and Lack of Puberty in a Woman With Mutated Estrogen Receptor β (ESR2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, her gonads were clearly abnormal (streak), a finding not observed in ESR1-deficient patients."
    explanation: The distinguishing feature stated by the authors.
notes: >-
  Do not read "ESR1 mutation" here as the breast cancer finding of the same
  name. The two are opposite lesions in one gene: the germline biallelic
  variants that cause this syndrome disable the receptor, while the somatic
  ESR1 variants that emerge under endocrine therapy in breast cancer activate
  it without ligand. PMID:42734155, cited on the receptor-signalling node
  below, is the review that sets the two side by side. The practical
  consequence for curation is that a literature search on the gene symbol
  alone returns mostly the breast cancer variants, so searches for this
  disease need the syndrome name or the insensitivity phrasing.

  No GeneReviews chapter exists for this disease; PubMed returns no chapter for
  estrogen resistance or estrogen in the title within the GeneReviews book. The
  entry is built from the primary case reports and the receptor's functional
  literature. Orphanet:785 is cross-referenced by the MONDO class but is not in
  the pre-cached Orphadata leaf set, so no Orphanet row is quoted here.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Estrogen_Resistance_Syndrome · 2026-09-29T20:10:37Z · View source

Seventh tranche of the estrogen-signalling work in issue #12925, the one disease in which ESR1 sits on a mechanism node by definition. Claim issue #13160. The IEMbase comparison note (IEMBASE-0130, July 2026) had judged this a true unmapped disease gap; no stub existed, so a stub was added in the commit before this one and retired by it. The MONDO cross-references are the phenotype record OMIM:615363 and Orphanet:785; OMIM:133430, which the IEMbase note recorded, is the ESR1 gene record, and the mapping justification says so. Aromatase_Deficiency is the differential, not the target. Deep research. falcon was requested and had no key in this environment, so the run used the recorded fallback and openscientist produced the report (fell_back, requested_provider and provider_attempts are in its frontmatter). Its reference validation resolved 17 of 17 citations with none off topic; four quoted claims were not found in the abstract-only sources, and none of those quotes is used here. Term validation was retro-fitted after a network reset aborted the in-run check: one invented HPO identifier (HP:0000783, offered as primary amenorrhea) and five mislabelled ones, none of which the entry uses; primary amenorrhea is bound to HP:0000786 from a live lookup. just preflight-dr passed: ESR1 named 39 times, OMIM 615363 matched. Three of the report's citations were adopted after reading their cached abstracts, the long-term follow-up of the first female case (PMID:32152632), the 1998 skeletal review (PMID:9554463) and the 2022 overview of congenital estrogen disorders (PMID:34538723). The report's circadian, AMH-promoter, cryo-EM, bisphenol and breast-cancer citations are about the receptor's biology or a different disease and were not used. Its suggested bisphosphonate therapy carries no source and was not added. Primary sources were found by PubMed title search rather than from the report: the 1994 index male (PMID:8090165) and his bone follow-up (PMID:18505767), the first female (PMID:23841731), the Algerian siblings (PMID:27754803), the Jordanian sisters (PMID:35134944), the 2024 adolescent case (PMID:39295121), the 2025 case with p.Met543Thr (PMID:40032016), the Q375H and R394H functional studies (PMID:32963012, PMID:32242619), the alpha-ERKO mouse (PMID:8248223), the ESR2 case used as a differential (PMID:30113650) and the 2026 review contrasting germline and somatic ESR1 variants (PMID:42734155). The heterozygous p.Ala207Thr variant in a woman with polycystic ovary syndrome (PMID:36401248) is excluded from the genetic record with the reason stated in its notes. No GeneReviews chapter exists; just check-genereviews reports NO_CHAPTER with synonyms present, and a PubMed book search agrees. Orphanet:785 could not be quoted because the Orphadata cache in this checkout has no record for it. Shape. The pathograph runs MOLECULAR (ESR1 loss of function, with genetic_context and GO:0030284 modifier LOSS_OF_FUNCTION, a qualitative loss of the receptor's own function) to CELLULAR (loss of receptor signalling, GO:0030520 ABSENT) and then branches to four consequences: loss of gonadotropin negative feedback (ORGANISM), failure of estrogen-dependent epiphyseal maturation and bone mineral accrual (TISSUE), failure of estrogen-dependent female reproductive development (TISSUE), and insulin resistance (ORGANISM). Every phenotype is reached by a causal edge. Two animal models are linked with readouts, the receptor-null mouse and the Q375H knock-in. The treatment record documents estrogen and diethylstilbestrol administration with REFUTE items for the skeletal and pubertal outcomes and one SUPPORT item for the metabolic benefit. Red-team review before opening the pull request found two blocking problems and they are fixed here. First, the description, the metabolic node and the inheritance block asserted as universal what the cached full text of PMID:23841731 contradicts: that proband lacked the pubertal growth spurt, stayed below the 50th height percentile, had a normal insulin resistance index, and was adopted with no parental samples. Tall stature and the metabolic phenotype are now reported as usual rather than invariable, with a REFUTE evidence item carrying the normal-metabolism sentence, and relatedness is stated for the four families that document it. Second, the skeletal node bundled growth-plate non-fusion with high-turnover bone loss, two mechanisms at one scale feeding different phenotypes; it is split into Failure of Epiphyseal Fusion and Increased Bone Resorption with Failed Mineral Accrual. The same review produced six further changes. GO:0030520 and GO:0071392 on the signalling node moved from ABSENT to DECREASED, because the ligand-binding-domain alleles retain measurable signalling at supraphysiological estradiol. The edge to the metabolic node moved from DIRECT to INDIRECT_UNKNOWN_INTERMEDIATES. Uterine hypoplasia (HP:0000013) and absent pubertal growth spurt (HP:0031087) were added as phenotypes, both quoted from cached sources. A progestin treatment was added: it is the only reported intervention that changes a phenotype in this disease, and the source reads the ovarian response as intact progesterone-receptor feedback. Tamoxifen was split out of the estrogen treatment, since a selective modulator is a different class. A hepatic binding-protein record was added as the cleanest biochemical readout of the resistance: those proteins do not rise despite high estradiol. Review round on PR #13174. The reviewer found that Enlarged polycystic ovaries had no inbound edge, so the entry was at 14 of 15 connected phenotypes and the pull request body claimed 15. The claim was stale rather than invented: the check had been run before a late edit that removed the ovarian target from the reproductive-development node's downstream list and did not re-home it. The count is now verified at 15 of 15 after the fix rather than carried over. The underlying modelling problem the reviewer identified was real. The reproductive-development node carried two mechanisms: the receptor failing in breast and uterus, and ovarian enlargement driven by unopposed gonadotropins. The gonadotropin-feedback node now points at the ovarian phenotype directly, carrying the sister-pair evidence and the mouse evidence, and the reproductive node is scoped to the two tissues the receptor fails in, losing its ovary and granulosa-cell bindings and its ovarian-follicle process term. Four further review items were taken. Three snippets were trimmed: one began with a reference superscript carried in from the full text, and two ended mid-parenthesis at a figure callout. The 204 cm height quoted in the Tall stature description is in the cached abstract and is now cited, with the imperial conversion truncated because bracketed spans are stripped before matching, alongside a REFUTE item recording the proband who had no growth spurt. The entry description no longer says estrogen action is simply absent, since the signalling node is deliberately DECREASED for the hypomorphic alleles. A diagnosis record was added, reusing the high-estradiol-with-high-gonadotropins signature, the unraised hepatic binding proteins, and ESR1 sequencing. Checks after the review round: validate, validate-terms and count-verified-snippets (89/89) pass; check-genereviews NO_CHAPTER; list-gene-term-mismatches finds both ESR1 bindings named by the entry; list-disconnected-phenotypes reports 15 of 15 phenotypes connected; check-entity-refs, check-causal-targets, check-duplicate-keys, check-qualifier-terms, check-enum-values and check-coarse-phenotypes pass. validate-disorders over the tranche and the remaining offline gates are recorded in the pull request.

OpenScientist ▸
Estrogen Resistance Syndrome (Estrogen Insensitivity Syndrome): A Comprehensive Disease Characteristics Report
openscientist-autonomous 17 citations 2026-09-29T16:00:40.544919

Estrogen Resistance Syndrome (Estrogen Insensitivity Syndrome): A Comprehensive Disease Characteristics Report

Target Disease: Estrogen Resistance Syndrome / Estrogen Insensitivity Syndrome (EIS) MONDO ID: MONDO:0014148 · OMIM: #615363 · Gene: ESR1 (HGNC:3467) Category: Mendelian, autosomal recessive Report compiled: 2026-09-29 (5-iteration autonomous investigation; 9 findings; 25 papers reviewed)

Summary

Estrogen Resistance Syndrome — more precisely termed Estrogen Insensitivity Syndrome (EIS) — is an ultra-rare autosomal-recessive Mendelian endocrine disorder caused by biallelic germline loss-of-function (LOF) variants in ESR1, the gene encoding estrogen receptor α (ERα). The defect renders peripheral target tissues unresponsive to estrogen despite high circulating 17β-estradiol (E2), producing a paradoxical picture of estrogen "deficiency" symptoms in the face of estrogen excess. This distinguishes true resistance (receptor defect, high E2) from estrogen deficiency disorders such as aromatase (CYP19A1) deficiency (low E2, rescued by estrogen therapy).

The clinical phenotype is dominated by the skeletal consequences of estrogen's role in epiphyseal maturation: affected individuals of both sexes lack the pubertal growth spurt, fail to fuse their epiphyses, continue linear growth into adulthood, reach very tall stature, and develop osteoporosis with elevated bone turnover. Metabolic derangements (glucose intolerance, hyperinsulinemia, dyslipidemia) and elevated gonadotropins/androgens accompany the picture because of impaired estrogen negative feedback. Females additionally present with absent breast development, primary amenorrhea, and multicystic ovaries. Critically, the syndrome is largely refractory to estrogen replacement — even high-affinity ligands such as diethylstilbestrol (DES) fail to induce secondary sexual characteristics — because the receptor itself is the lesion.

At the molecular level, EIS mutations disrupt distinct layers of ERα signaling — ligand binding, DNA interaction, coactivator (SRC-3/NCOA3 and p300/EP300) recruitment, nuclear trafficking, and transcriptional regulation — that converge on a shared resistance phenotype. Confirmed pathogenic variants span a truncating null (p.Arg157Ter, the original 1994 male index case) and hypomorphic ligand-binding-domain missense changes (p.Gln375His, p.Arg394His). ESR1 is strongly constraint-depleted for loss-of-function in gnomAD (pLI ≈ 1.0, LOEUF 0.37, missense Z = 2.99), which explains the extreme rarity of complete-null EIS. Knock-in and knockout mouse models (αERKO; Esr1-Q) phenocopy the human disease, confirming causality. Management remains supportive; there is no curative therapy.

1. Disease Information

Overview. Estrogen Resistance Syndrome (Estrogen Insensitivity Syndrome, EIS) is a Mendelian disorder in which target tissues cannot respond to estrogen because of loss-of-function mutations in the estrogen receptor α gene (ESR1). Despite normal or markedly elevated circulating estradiol, downstream estrogen-dependent processes — pubertal growth, epiphyseal fusion, bone mineralization, reproductive tract maturation, and metabolic homeostasis — fail. It is the receptor-level counterpart of aromatase deficiency, which produces a similar skeletal picture through estrogen absence rather than resistance.

Key identifiers.

Resource Identifier
OMIM (phenotype) #615363 (Estrogen resistance)
OMIM (gene) 133430 (ESR1*)
MONDO MONDO:0014148
Gene / HGNC ESR1 / HGNC:3467
Ensembl ENSG00000091831
UniProt P03372 (ESR1_HUMAN)
Cytogenetic locus 6q25.1–q25.2
Gene aliases ER, ESR, ESRA, NR3A1

ICD-10/ICD-11, MeSH, and Orphanet do not assign a distinct code for this ultra-rare entity; it is generally captured under disorders of estrogen action / hormone receptor abnormalities.

Synonyms and alternative names. Estrogen Resistance; Estrogen Insensitivity Syndrome (EIS); ERα resistance; ESR1-related estrogen insensitivity. A recent review reframes the condition as "the 'Upside Down' of ESR1 mutations," contrasting germline LOF (this disease) with somatic gain-of-function ligand-binding-domain mutations in breast cancer (PMID: 42734155).

Data provenance. The evidence base is derived almost entirely from aggregated disease-level resources (OMIM, ClinVar, gnomAD) and a small number of individual patient case reports — this is a literature composed of single-case and small-family reports rather than EHR cohorts or registries, reflecting the disease's extreme rarity.

2. Etiology

Primary cause (genetic). EIS is caused by biallelic germline loss-of-function variants in ESR1 (estrogen receptor α). These impair ERα function and render peripheral tissues insensitive to circulating E2 (Finding F001). Two independent reviews confirm the causal gene and mechanism:

"germline ESR1 mutations cause EIS by impairing ERα function and rendering peripheral tissues insensitive to circulating E2" — PMID: 42734155

"Germline loss-of-function variants in ESR1, the gene encoding estrogen receptor α, are known to cause of estrogen insensitivity/resistance" — PMID: 34538723

Genetic risk factors. - Causal variants: truncating (nonsense) p.Arg157Ter and hypomorphic missense p.Gln375His, p.Arg394His (see Section 4). - Consanguinity: because the disorder is autosomal recessive, parental relatedness is an important risk factor. A homozygous ESR1 case was reported in a 13-year-old girl of consanguineous parents (PMID: 39295121, Finding F006). - Modifier / background genes: in mouse models, genetic background strongly modifies the ovarian transdifferentiation phenotype of estrogen-receptor knockouts (a Chr18 locus was implicated; PMID: 39576259), suggesting modifier effects may shape expressivity.

Environmental / non-genetic risk factors. None established as causal. The disease is monogenic; environmental exposure is not a recognized trigger. Sex modifies presentation (females show the reproductive phenotype) but not disease risk.

Protective factors. No genetic or environmental protective factors are established. Given the disorder is caused by complete/partial receptor loss, the theoretical "protective" allele is simply a functional ESR1 allele; heterozygous carriers are largely unaffected (recessive inheritance), though rare heterozygous variants (e.g., p.A207T) have been associated with partial insensitivity/PCOS-like phenotypes (PMID: 36401248).

Gene–environment interactions. Not characterized for this monogenic disease. The dominant "environmental" interface is pharmacological: because the receptor is defective, exogenous estrogens (the usual environmental/therapeutic estrogen input) fail to signal — a gene–treatment interaction that defines the disease's therapeutic refractoriness.

3. Phenotypes

EIS is a multi-system disorder. Phenotypes derive from case reports and are consistent across estrogen-resistance and estrogen-deficiency (aromatase) states, which share a skeletal/metabolic core.

Phenotype Type Onset Severity Frequency Suggested HPO
Absent pubertal growth spurt Clinical sign Adolescence Severe Both sexes, characteristic HP:0008819 (Abnormal pubertal development)
Unfused / delayed epiphyses Radiographic sign Adolescence–adult Severe Characteristic HP:0002644 (Delayed epiphyseal ossification)
Continued linear growth / tall stature Physical Adult Severe Both sexes HP:0000098 (Tall stature)
Delayed bone age Radiographic Childhood–adolescence Moderate–severe Characteristic HP:0002750 (Delayed skeletal maturation)
Osteoporosis / reduced BMD Lab/imaging Young adult Severe Both sexes HP:0000939 (Osteoporosis)
Increased bone turnover Lab abnormality Adult Moderate Characteristic HP:0003155 (Elevated alkaline phosphatase)
Glucose intolerance / hyperinsulinemia Lab abnormality Adult Moderate Reported HP:0000842 (Hyperinsulinemia)
Dyslipidemia Lab abnormality Adult Moderate Reported HP:0003119 (Abnormal circulating lipid concentration)
Elevated gonadotropins (LH/FSH) Lab abnormality Adolescence–adult — Characteristic HP:0000837 (Hypergonadotropic hypogonadism–related)
Elevated estrogens Lab abnormality Adolescence–adult — Characteristic (defines resistance) —
Absent breast development (female) Physical Puberty Severe Female HP:0003186 (Breast hypoplasia)
Primary amenorrhea (female) Clinical sign Puberty Severe Female HP:0000783 (Primary amenorrhea)
Multicystic ovaries (female) Imaging Adolescence Moderate Female HP:0000137 (Abnormality of the ovary)
Poor uterine growth (female) Imaging Adolescence Moderate Female HP:0000013 (Hypoplasia of the uterus)

Evidence. The skeletal/metabolic core is documented in the landmark pediatric-endocrinology review:

"absence of the pubertal growth spurt, delayed bone maturation, unfused epiphyses, continued growth into adulthood and very tall adult stature in both sexes" — PMID: 9554463 (Finding F002)

"Glucose intolerance, hyperinsulinemia and lipid abnormalities are also present. Skeletal integrity is compromised. Increased bone turnover, reduced bone mineral density and osteoporosis develop in both sexes" — PMID: 9554463

The female reproductive phenotype comes from the first fully characterized female case:

"she presented with lower abdominal pain, absent breast development, primary amenorrhea, and multicystic ovaries" — PMID: 32152632 (Finding F003)

Notably preserved. Normal male sexual maturation/virilization is preserved because it is androgen-dependent, not estrogen-dependent — one of the key clues that distinguishes estrogen resistance from broader hypogonadism.

Quality-of-life impact. No formal EQ-5D/SF-36/PROMIS data exist for this ultra-rare disease. Inferred burdens are substantial: lifelong osteoporosis (fracture risk), infertility, tall stature with its psychosocial dimension, and metabolic complications. QoL data represent a knowledge gap.

4. Genetic / Molecular Information

Causal gene. ESR1 (estrogen receptor α; HGNC:3467; OMIM *133430; ENSG00000091831; UniProt P03372; locus 6q25.1–q25.2). ERα is a nuclear-hormone-receptor transcription factor (NR3A1) with a modular structure: N-terminal domain (NTD, containing ligand-independent AF-1), DNA-binding domain (DBD), and C-terminal ligand-binding domain (LBD, containing ligand-dependent AF-2).

Pathogenic variants (ClinVar-confirmed, conditioned on "Estrogen resistance syndrome"; Finding F009):

Variant (NM_000125.4) Protein Type ClinVar classification Note
c.469C>T p.Arg157Ter Nonsense (null) Pathogenic Classic homozygous truncating variant; original male index case (Smith 1994)
c.1125G>T p.Gln375His Missense (LBD, hypomorphic) Pathogenic Modeled in Esr1-Q knock-in mouse
c.1181G>A p.Arg394His Missense (LBD) Pathogenic / Likely pathogenic Alters ligand–receptor conformation
c.804G>C p.Lys268Asn Missense Uncertain significance Combined-condition listing
c.433G>A p.Gly145Ser Missense Uncertain significance Combined-condition listing
c.619G>A p.Ala207Thr Missense (heterozygous) Reported Partial insensitivity / PCOS-like, IVF poor response (PMID: 36401248)

Variant classification & spectrum. Of 262 total ClinVar ESR1 records (retrieved 2026), 44 are annotated Pathogenic and 3 Likely pathogenic — but many "Pathogenic" entries are large 6q25 copy-number changes (contiguous-gene deletions/duplications) or somatic breast-cancer variants, not germline EIS. The germline EIS spectrum is small and dominated by the three variants above.

Allele frequency & population constraint (Finding F008; gnomAD, computational, retrieved 2026):

Metric Value Interpretation
pLI 0.99998 Extreme intolerance to heterozygous LoF
oe_lof (observed/expected LoF) 0.228 (90% CI 0.146–0.369) LOEUF ≈ 0.37 — strongly LoF-constrained
obs_lof vs exp_lof 12 vs 52.7 ~77% depletion of protein-truncating variants
Missense Z 2.99 Missense-constrained
Synonymous Z 0.39 Neutral (as expected)

This strong constraint explains why complete-null biallelic EIS is exceptionally rare: LoF alleles are purged from the population, so two must co-occur (typically via consanguinity) to produce disease.

Functional consequences. Loss of function (nonsense null: no functional receptor; hypomorphic missense: reduced/abolished transactivation). EIS mutations "change conformation of ligand-receptor complex" and produce "altered transcriptome profile" (PMID: 32242619, Finding F004). There is no dominant-negative or gain-of-function mechanism in germline EIS (contrast with somatic Y537S/D538G gain-of-function LBD mutations in breast cancer).

Modifier genes. Mouse data implicate a Chr18 background locus modifying the ERKO ovarian phenotype (PMID: 39576259); human modifiers are not defined.

Epigenetic information. EIS mutants Q375H and R394H show a differential DNA-methylome as well as transcriptome vs wild-type ERα (PMID: 32242619), indicating the receptor defect propagates to epigenetic reprogramming of estrogen-target loci. Beyond this, disease-specific epigenetic data are limited.

Chromosomal abnormalities. Large 6q25 copy-number variants involving ESR1 appear in ClinVar as contiguous-gene events but are distinct from the classic point-mutation EIS.

5. Environmental Information

  • Environmental factors: None established as causal. This is a monogenic disease.
  • Xenoestrogens (mechanistic relevance, not causal): Environmental estrogen mimics (bisphenols BPA, BPAF, BPC) act through ERα and depend on the AF-1/NTD domain for agonist activity (PMID: 42224247). In EIS, a defective receptor blunts responses to both endogenous and environmental estrogens — relevant to why exogenous estrogenic compounds fail therapeutically.
  • Lifestyle factors: No causal role. Standard bone-health measures (weight-bearing exercise, calcium/vitamin D) are supportive but do not modify the underlying receptor defect.
  • Infectious agents: Not applicable. No pathogen is implicated.

6. Mechanism / Pathophysiology

Ordered causal chain

  1. Biallelic germline ESR1 LOF mutation (nonsense p.Arg157Ter or hypomorphic LBD missense p.Gln375His / p.Arg394His) → produces a non-functional or transcriptionally impaired ERα (demonstrated: ClinVar pathogenic classification; molecular-dynamics conformational change, PMID: 32242619).
  2. Non-functional ERα → fails to bind ligand and/or fails to adopt the active conformation upon estradiol binding (demonstrated by MD simulation: "both ESR1 mutations change the ERα conformation of the ligand-receptor complexes").
  3. Impaired active receptor → fails to recruit coactivators SRC-3 (NCOA3) and p300 (EP300) at estrogen-response elements (mechanistically demonstrated by cryo-EM of the active complex, PMID: 25728767; AF-1/AF-2 cooperation, PMID: 39432505).
  4. Failed coactivator recruitment → loss of estrogen-responsive transcription and altered transcriptome + DNA methylome (demonstrated in EIS mutants, PMID: 32242619).
  5. Loss of estrogen-target transcription in bone (growth-plate chondrocytes/osteoblasts) → failure of the pubertal growth spurt and of epiphyseal fusion → continued linear growth → tall stature; and reduced bone mineralization → osteoporosis with high bone turnover (demonstrated clinically, PMID: 9554463).
  6. Branch — hypothalamic–pituitary axis: Loss of ERα-mediated estrogen negative feedback → elevated LH/FSH and androgens despite high estradiol (demonstrated: normal pulsatile LH but elevated mean LH with markedly increased estrogens, PMID: 32152632).
  7. Branch — female reproductive tract: Loss of ERα signaling → absent breast development, poor uterine growth, primary amenorrhea, multicystic ovaries (demonstrated, PMID: 32152632, PMID: 39295121).
  8. Branch — metabolism/vasculature: Loss of ERα action → glucose intolerance, hyperinsulinemia, dyslipidemia (clinical, PMID: 9554463); loss of ERα-mediated eNOS enhancement → inferred increased vascular risk (mechanism from ER-α agonist/eNOS studies, PMID: 28736253).
  9. Because the lesion is the receptor itself → exogenous estrogen (even high-affinity DES) cannot restore signaling → therapeutic refractoriness (demonstrated, PMID: 32152632).

Detail by category

Molecular pathways. Nuclear-receptor (ERα/NR3A1) genomic signaling: ligand binding → receptor dimerization → DNA binding at estrogen-response elements → coactivator recruitment (SRC-3/NCOA3, p300/EP300) → RNA-Pol-II transcription. Cryo-EM shows "each of the two ligand-bound ERα monomers independently recruits one SRC-3 protein via the transactivation domain of ERα; the two SRC-3s in turn bind to different regions of one p300 protein" (PMID: 25728767, Finding F005). Non-genomic (membrane GPER) signaling contributes to some tissues but cannot compensate for ERα loss.

Protein dysfunction. Nonsense p.Arg157Ter → truncation/loss of protein. LBD missense (Q375H, R394H) → conformational distortion of the ligand–receptor complex impairing AF-2/coactivator surface function. The AF-1 (NTD) domain normally collaborates with the C-terminal LBD(AF-2) for coactivator recruitment (PMID: 39432505); disruption at either pole impairs the assembly.

Signaling nodes disrupted. Germline EIS mutations "disrupt distinct layers of ERα signaling, including ligand binding, DNA interaction, coactivator recruitment, nuclear trafficking, transcriptional regulation" (PMID: 42734155, Finding F005).

Cellular processes. Growth-plate chondrocyte senescence/epiphyseal fusion (estrogen-driven) fails; osteoblast/osteoclast coupling is dysregulated (increased bone turnover). In gonads, ERα loss can drive granulosa-to-Sertoli-like transdifferentiation in mouse models (PMID: 39576259).

Metabolic changes. Glucose intolerance, hyperinsulinemia, and lipid abnormalities reflect loss of ERα's role in insulin sensitivity and lipid handling (PMID: 9554463).

Broad ERα physiology (why the phenotype is pleiotropic; Finding F007). ERα is expressed across bone, reproductive tract, testis (Sertoli cells), vasculature, brain, and metabolic tissues. In testis, ERα directly regulates AMH transcription: "estrogens can stimulate AMH production because estrogen receptors are present in Sertoli cells and aromatase is stimulated by FSH" and "The direct effects of sex steroids on AMH transcription are mediated by androgen receptor and estrogen receptor α action" (PMID: 35712256; mechanism confirmed via ERE on the hAMH promoter, PMID: 32934281). ERα also mediates estrogen's eNOS-enhancing vasoprotection (PMID: 28736253) and modulates circadian rhythms via classical ERE-dependent action (PMID: 24527952). This ubiquitous distribution explains the simultaneous skeletal, metabolic, vascular, and reproductive manifestations, while androgen-dependent male virilization is spared.

Suggested ontology terms. - GO biological process: GO:0030520 (intracellular estrogen receptor signaling pathway); GO:0006357 (regulation of transcription by RNA Pol II); GO:0030282 (bone mineralization); GO:0001503 (ossification). - GO cellular component: GO:0005634 (nucleus); GO:0005667 (transcription regulator complex). - CL cell types: CL:0000062 (osteoblast); CL:0000138 (chondrocyte); CL:0000216 (Sertoli cell); CL:0000501 (granulosa cell). - CHEBI: CHEBI:16469 (17β-estradiol); CHEBI:41922 (diethylstilbestrol).

7. Anatomical Structures Affected

Organ level (primary). - Skeleton / bone (UBERON:0002481 bone tissue; UBERON:0001474 bone element) — growth plates, epiphyses; the dominant target. - Reproductive organs (female): ovary (UBERON:0000992), uterus (UBERON:0000995), breast/mammary gland (UBERON:0001911). - Hypothalamic–pituitary axis (UBERON:0001898 hypothalamus; UBERON:0000007 pituitary gland) — impaired negative feedback.

Secondary / body-system involvement. - Endocrine system (elevated gonadotropins, androgens). - Metabolic/endocrine (pancreas/insulin axis — glucose intolerance, hyperinsulinemia). - Cardiovascular system (inferred increased risk via loss of ERα/eNOS vasoprotection).

Tissue/cell level. Epithelial (mammary, uterine), connective/skeletal (bone, cartilage growth plate), and gonadal cells. Specific cell populations: growth-plate chondrocytes (CL:0000138), osteoblasts (CL:0000062) and osteoclasts, ovarian granulosa cells (CL:0000501), and Sertoli cells (CL:0000216, via AMH regulation).

Subcellular level. ERα is a nuclear/cytoplasmic shuttling receptor: nucleus (GO:0005634, site of transcriptional action) and cytoplasm (inactive receptor pool). Nuclear trafficking is itself one of the disrupted signaling layers in EIS.

Localization / lateralization. Systemic and bilateral (skeleton, paired gonads); no lateralized predilection.

8. Temporal Development

Onset. Congenital genetic defect, but clinically silent until puberty, when the absence of estrogen action becomes manifest (failure of pubertal growth spurt, absent breast development, primary amenorrhea). Presentation is therefore typically adolescent (case reports at ages 13–15; PMID: 39295121, PMID: 32152632). Onset pattern is insidious/chronic.

Progression. Chronic, lifelong, non-remitting. Because epiphyses do not fuse, linear growth continues into adulthood, and skeletal complications (osteoporosis, high bone turnover) are progressive without effective intervention. No spontaneous remission occurs.

Critical periods. Puberty and young adulthood are the windows of maximal skeletal vulnerability (failed peak-bone-mass accrual, ongoing growth). This is also the window where any effective therapy would need to act — but estrogen replacement is ineffective owing to receptor resistance, so the "therapeutic window" is functionally closed with current tools.

9. Inheritance and Population

Epidemiology. Ultra-rare; no reliable prevalence or incidence estimate exists — the world literature comprises a handful of individual cases and small families. Orphanet does not list a discrete prevalence figure.

Inheritance. Autosomal recessive. Biallelic ESR1 LOF is required; affected individuals are typically homozygous (e.g., p.Arg157Ter, or homozygous variants in consanguineous families) or compound heterozygous. Heterozygous carriers are generally unaffected, though rare heterozygous variants may confer partial phenotypes.

  • Penetrance: Appears high/complete for the biallelic-null genotype (based on limited cases).
  • Expressivity: Variable — sex determines the reproductive component; missense hypomorphs may be milder than nulls.
  • Genetic anticipation: Not applicable (not a repeat-expansion disorder).
  • Germline mosaicism: Not reported.
  • Founder effects: None established.
  • Consanguinity: Contributory — expected for a rare recessive disorder; documented in a homozygous case (PMID: 39295121, Finding F006).
  • Carrier frequency: Not established; gnomAD shows ESR1 LoF alleles are strongly depleted (obs_lof 12 vs exp 52.7; pLI ≈ 1.0), implying carriers are rare.

Population demographics. No ethnic or geographic clustering established (too few cases). Sex ratio: both sexes affected by the skeletal/metabolic phenotype; females additionally show reproductive manifestations, so ascertainment may skew toward females at puberty. Age distribution: predominantly adolescent/young-adult at diagnosis.

10. Diagnostics

Biochemical hallmark (the diagnostic key). Elevated circulating estradiol with elevated gonadotropins (LH, FSH) and androgens, in the presence of absent estrogen effect. This combination — high E2 and high LH/FSH — distinguishes resistance from deficiency:

normal pulsatile LH secretion with elevated mean LH and mildly elevated FSH "despite markedly increased estrogens" — PMID: 32152632

Laboratory tests. Serum estradiol (high), LH and FSH (high), testosterone/androgens (elevated), bone-turnover markers (elevated). Metabolic panel: fasting glucose/insulin (glucose intolerance, hyperinsulinemia), lipid profile (dyslipidemia).

Imaging / functional. Bone-age radiographs (delayed, unfused epiphyses); DXA (reduced bone mineral density/osteoporosis); pelvic ultrasound in females (poor uterine growth, multicystic ovaries).

Genetic testing — the confirmatory test. Molecular analysis of ESR1: - Single-gene ESR1 sequencing or targeted panel (hypogonadism / disorders-of-sex-development / skeletal panels including ESR1, CYP19A1, ESR2). - Whole-exome sequencing (WES) is highly useful for undiagnosed cases — the p.A207T variant was found via WES (PMID: 36401248). - Chromosomal microarray for the rare 6q25 contiguous-gene deletions/duplications. - Interpret variants per ACMG/AMP against ClinVar (pathogenic: p.Arg157Ter, p.Gln375His, p.Arg394His).

Functional / research diagnostics. In-vitro transactivation assays screening candidate ligands against the patient's variant receptor (a 75-compound screen showed DES could transactivate the variant in vitro even though it failed clinically; PMID: 32152632); transcriptome/DNA-methylome profiling distinguishing mutant vs wild-type ERα (PMID: 32242619).

Differential diagnosis.

Condition Gene Estradiol Key distinguisher
Estrogen resistance (EIS) ESR1 High Receptor defect; refractory to estrogen
Aromatase deficiency CYP19A1 Low Estrogen absent; rescued by estrogen therapy
ERβ (ESR2) defect ESR2 Variable Streak gonads (46,XX) — "her gonads were clearly abnormal (streak), a finding not observed in ESR1-deficient patients" (PMID: 30113650)
Complete androgen insensitivity AR — Androgen (not estrogen) axis; different karyotype context
Hypergonadotropic hypogonadism (other) various Low Low sex steroids

Screening. No newborn/population screening exists (disease too rare, no actionable neonatal intervention). Cascade genetic testing of relatives in known families and carrier testing in consanguineous couples are appropriate.

11. Outcome / Prognosis

Survival / mortality. Not a directly lethal disease; no life-expectancy or mortality data exist for this ultra-rare condition. Longevity is presumed near-normal, but long-term cardiovascular and metabolic risks (from loss of ERα vasoprotection and insulin resistance) are theoretically increased and unquantified.

Morbidity / function. Principal long-term morbidity is skeletal: osteoporosis with elevated fracture risk from failure to accrue peak bone mass, plus the functional and psychosocial consequences of tall stature and unfused epiphyses. Infertility (female) is a major reproductive morbidity. Metabolic complications (glucose intolerance, dyslipidemia) add chronic-disease burden.

Disease course / recovery. Chronic and lifelong with no natural recovery; the receptor defect is permanent. Bone density and reproductive function do not respond to standard estrogen therapy (refractoriness demonstrated over 2.5 years of DES; PMID: 32152632).

Prognostic factors. Variant type likely governs severity: null alleles (p.Arg157Ter) predict complete resistance, whereas hypomorphic missense alleles (Q375H, R394H) may retain partial function and milder phenotypes. This is inferred from genotype–phenotype patterns and in-vitro/mouse data (PMID: 32242619), not from formal prognostic studies.

12. Treatment

There is no curative or reliably effective therapy. Because the lesion is the estrogen receptor itself, conventional estrogen replacement — the logical treatment for estrogen-deficiency states — is ineffective:

"DES treatment did not induce secondary sexual characteristics in our patient. Treatment with DES was not successful in our patient. She remains hypoestrogenic" — PMID: 32152632 (Finding F003)

Pharmacotherapy (attempted / supportive). - High-affinity estrogenic ligands (e.g., diethylstilbestrol, DES; high-dose estradiol): attempted on the rationale that a stronger ligand might drive a hypomorphic receptor; some variants are transactivatable in vitro, but clinical response is generally absent for null/severe alleles. NCIT: C2242 (Estrogen); C542 (Diethylstilbestrol). - Bone-directed supportive therapy: calcium, vitamin D; bisphosphonates for osteoporosis are a rational (though unproven-in-EIS) option to address high bone turnover. NCIT: C1454 (Bisphosphonate). - Metabolic management: standard management of glucose intolerance/dyslipidemia.

Personalized / experimental directions (conceptual). - Variant-tailored ligand screening: matching a specific hypomorphic receptor to a ligand that restores its transactivation (in-vitro screen approach; PMID: 32152632). - Reproductive management in partial insensitivity: in a heterozygous PCOS/partial-insensitivity patient undergoing IVF, recognition of ESR1 insensitivity informed ovarian-stimulation strategy (PMID: 36401248). - Model-guided approaches: the Esr1-Q knock-in mouse was used to explore progestogen + GnRH-inhibitor strategies to reverse impaired female reproductive-tract function (PMID: 32242619) — preclinical only. - Gene/RNA therapy: no clinical programs exist; conceptually, gene replacement/editing of ESR1 would be required to address the root cause. Not available.

Note on breast-cancer therapeutics. The rich pharmacology targeting ERα (SERMs, SERDs such as fulvestrant, oral SERDs, ER-PROTACs like vepdegestrant/ARV-471) is directed at gain-of-function somatic ESR1 mutations in breast cancer and is not applicable to germline LOF EIS — indeed these agents antagonize/degrade ERα, the opposite of what EIS needs.

No NCIT-coded standard-of-care regimen exists for EIS.

13. Prevention

  • Primary prevention: Not possible for a germline monogenic disorder. Genetic counseling for consanguineous couples and families with a known ESR1 variant is the principal preventive tool. Carrier testing and, where desired, preimplantation genetic diagnosis (PGD) or prenatal testing can prevent affected births in known-risk families.
  • Secondary prevention: Early recognition of the biochemical signature (high E2 + high gonadotropins + delayed bone age) enables early diagnosis and initiation of supportive bone-protective measures.
  • Tertiary prevention: Osteoporosis management (calcium, vitamin D, ± bisphosphonates), metabolic surveillance and management, and monitoring for cardiovascular risk to prevent complications.
  • Immunization / public health / environmental interventions: Not applicable.

14. Other Species / Natural Disease

  • Taxonomy / orthologs: ESR1 is highly conserved across vertebrates. Mouse Esr1 (NCBI Gene 13982) is the principal model ortholog; rat, zebrafish, and other vertebrate orthologs exist.
  • Natural disease: No well-characterized spontaneous ESR1-LOF "estrogen resistance syndrome" is documented in companion animals or wildlife (no OMIA entry emerged in this investigation). The comparative evidence is from engineered models, not naturally occurring disease.
  • Comparative biology: Estrogen-receptor knockout phenotypes are conserved in principle (infertility, skeletal and metabolic effects), but details are strain/background-dependent in mice (PMID: 39576259).
  • Transmission / zoonosis: Not applicable (genetic, non-communicable).

15. Model Organisms

Mouse (principal model).

Model Type Key phenotype Relevance to EIS
αERKO (Esr1 knockout) Constitutive knockout Infertile (both sexes), absent mammary development, skeletal & metabolic abnormalities Recapitulates human ERα-null EIS
Esr1-Q knock-in (models human Q375H) CRISPR/Cas9 knock-in Infertile male & female mice; "similar phenotypes to αERKO mice"; corresponds to human Q375H patient Directly recapitulates a specific human EIS variant (PMID: 32242619, Finding F004)
Ex3αβERKO / αβERKO (double ERα/ERβ KO) Knockout Ovarian transdifferentiation to seminiferous-tubule-like structures (background-dependent) Reveals ERα role in gonad maintenance (PMID: 39576259)
NERKI ("non-classical" ER knock-in) Knock-in (ERE-binding mutant) Loss of classical genomic estrogen effects on circadian activity Dissects genomic vs non-genomic ERα action (PMID: 24527952)
ERβ (ESR2) knockout Knockout Subfertile (reduced ovarian efficiency); otherwise grossly normal Control demonstrating ERβ ≠ ERα roles (PMID: 9861029)

"Female and male Esr1-Q mice are infertile and have similar phenotypes to αERKO mice" — PMID: 32242619

In-vitro / cellular models. HeLa and MCF-7 luciferase reporter-gene transactivation assays for ERα variants; the SMAT1 prepubertal Sertoli-cell line for AMH-promoter/ERE studies (PMID: 32934281); structural biology (cryo-EM of the DNA-bound ERα–SRC-3–p300 complex, PMID: 25728767).

Model characteristics. The Esr1-Q knock-in provides excellent face and construct validity for a human hypomorphic EIS variant (infertility phenocopying αERKO). Limitations: mouse skeletal biology (continuous growth plates, no true "epiphyseal fusion" event) does not perfectly model the human tall-stature/unfused-epiphysis phenotype; genetic background strongly modifies gonadal outcomes; and murine models cannot capture human psychosocial/QoL dimensions.

Resources. MGI (mouse Esr1), IMPC/IMSR for knockout lines; NCBI Gene for orthologs.

Mechanistic Model / Interpretation

   Biallelic germline ESR1 LOF
   (p.Arg157Ter null / Q375H, R394H hypomorph)
      |
      v
   Non-functional or conformationally
   distorted ERα protein  ──────────────┐ (LBD mutants: MD-confirmed
      |                          │  conformational change)
      v                          │
   Fails to bind ligand / adopt          │
   active conformation on E2 binding     │
      |                          │
      v                          │
   Fails to recruit SRC-3 (NCOA3) + p300 (EP300)
   at estrogen-response elements
      |
      v
   Loss of estrogen-responsive transcription
   + altered transcriptome & DNA methylome
      |
   ┌──────────┼───────────────┬────────────────┬───────────────┐
   v          v               v                v               v
 BONE     HYPOTHAL-       FEMALE            METABOLISM      VASCULATURE
 growth   PITUITARY       REPRO TRACT       glucose         loss of
 plate    loss of neg.    absent breast,    intolerance,    eNOS
 |        feedback        amenorrhea,       hyperinsulin-   enhancement
 |        |               poor uterus,      emia,           |
 v        v               multicystic       dyslipidemia    v (inferred)
 no       high LH/FSH,    ovaries           |               increased
 growth   high androgens  |                 v               vascular
 spurt,   DESPITE         v                 chronic         risk
 unfused  high E2         infertility       metabolic
 epiphyses|                                 disease
 |        |
 v        v
 tall stature,          ── HIGH ESTRADIOL + HIGH GONADOTROPINS ──
 osteoporosis,             = the biochemical fingerprint of
 high bone turnover        RESISTANCE (vs. deficiency)

   Because the RECEPTOR is the lesion →
   exogenous estrogen (even DES) cannot rescue → THERAPY REFRACTORY

The unifying insight is that a single receptor defect propagates into a pleiotropic, multi-system disease because ERα is a hub transcription factor deployed across bone, gonad, hypothalamus, metabolic, and vascular tissues. The paradox that patients look estrogen-deficient while being estrogen-replete is diagnostically decisive and mechanistically inevitable: the hormone is present but cannot be "heard." The same logic dictates the therapeutic dead-end — you cannot fix a broken receiver by shouting louder.

Evidence Base

PMID Title (abbrev.) Type Supports
42734155 EIS: the 'Upside Down' of ESR1 mutations Review F001, F005 — causal LOF mechanism; disrupted signaling layers
34538723 Congenital disorders of estrogen biosynthesis and action Review F001 — germline LOF ESR1 causes resistance
9554463 Essential roles of estrogens in pubertal growth... Landmark review F002 — skeletal & metabolic phenotype
32152632 Long-term follow-up of a female with complete estrogen insensitivity Case report F003 — female phenotype; treatment refractoriness
32242619 ESR1 mutations... change conformation & altered transcriptome Functional + model F004 — conformational mechanism; Esr1-Q mouse
25728767 Structure of a biologically active ER–coactivator complex on DNA Structural F005 — SRC-3/p300 coactivator assembly
39432505 AF-1 domain interacts with AF-2 LBD to recruit coactivators Functional F005 — AF-1/AF-2 cooperation
39295121 EIS in a female adolescent — case report Case report F006 — recessive/consanguineous homozygous case
30113650 Ovarian failure with mutated ESR2 Case report F006 — ESR2 differential (streak gonads)
35712256 AMH regulation by steroids in testis Review F007 — ERα breadth (Sertoli/AMH)
32934281 AMH elevation in hyperoestrogenic states In vitro F007 — ERα→ERE→AMH mechanism
28736253 Selective ER-α agonist & vascular dysfunction Animal F007 — ERα/eNOS vasoprotection
36401248 Novel ESR1 mutation in PCOS woman (p.A207T) Case report Heterozygous partial insensitivity; WES utility
9861029 Mice lacking ERβ Model ERβ vs ERα role (differential)
39576259 Ovarian transdifferentiation in absence of ER signaling Model Background modifiers; gonad maintenance
24527952 ESR1 modulates circadian rhythms Model Classical vs non-classical ERα action
42224247 Bisphenols agonist/antagonist for ERα In vitro Xenoestrogen relevance; AF-1 dependence

Computational/database evidence: gnomAD constraint (F008) and ClinVar variant curation (F009) were retrieved directly (2026) and provide the population-genetics and variant-classification backbone.

Somatic ESR1 breast-cancer literature (PMIDs 42714671, 42693657, 42665030, 42609450, 42603649, 42599237, 42593925, 22245602) was reviewed and explicitly set aside as not applicable to germline LOF EIS — it concerns gain-of-function LBD mutations and ERα-targeting/degrading therapeutics, the mechanistic inverse of this disease. This distinction is itself an important finding (the "Upside Down" framing).

Limitations and Knowledge Gaps

  1. Extreme rarity → thin evidence. The entire clinical picture rests on a handful of case reports. There are no prevalence/incidence figures, no mortality/survival data, and no formal QoL measurements.
  2. Genotype–phenotype correlation is under-powered. With so few variants (essentially p.Arg157Ter, p.Gln375His, p.Arg394His, plus VUS), the mapping from allele severity to clinical severity is inferred, not established.
  3. No approved or proven therapy. Estrogen replacement is refractory; bisphosphonate/metabolic management is extrapolated, not EIS-validated. No gene-therapy or ligand-rescue strategy has reached the clinic.
  4. Epigenetic/omics data are single-study. The transcriptome/methylome findings (PMID: 32242619) need replication across variants and tissues.
  5. Model-organism gaps. Mice do not fuse epiphyses as humans do, limiting fidelity for the tall-stature/unfused-epiphysis phenotype; background effects confound gonadal phenotypes.
  6. Cardiovascular/long-term outcome risk is inferred, not measured, in patients.
  7. Ontology coding is incomplete at the resource level (no dedicated ICD/Orphanet code), complicating knowledge-base integration.

Proposed Follow-up Experiments / Actions

  1. Establish an international EIS registry (case aggregation via GeneMatcher/networks) to derive prevalence, natural-history, and genotype–phenotype data — the single highest-impact action given how case-limited the field is.
  2. Systematic variant-function mapping: transactivation, coactivator-recruitment, and DNA-binding assays for every reported ESR1 germline variant, paired with molecular-dynamics conformational analysis, to build a functional matrix that predicts severity and ligand-rescuability.
  3. Ligand-rescue screening for hypomorphic alleles: high-throughput screening of ER ligands/SERMs against patient-specific hypomorphic receptors (extending the 75-compound approach in PMID: 32152632) to identify variant-tailored agonists.
  4. Preclinical therapy testing in Esr1-Q knock-in mice: evaluate bisphosphonates for the skeletal phenotype and the progestogen + GnRH-inhibitor strategy for reproductive-tract function (PMID: 32242619); assess AAV gene-replacement feasibility.
  5. Long-term metabolic/cardiovascular surveillance protocol for known patients to quantify the inferred vascular/insulin-resistance risk.
  6. Multi-tissue omics in patient-derived cells (iPSC → osteoblast/chondrocyte/granulosa models) to map the estrogen-target transcriptional program lost in EIS and identify downstream druggable nodes that bypass ERα.
  7. Formal ontology curation: submit dedicated disease codes and complete HPO/GO/CL/UBERON/CHEBI/NCIT annotation (as compiled in this report) to improve knowledge-base interoperability.

Report generated by autonomous scientific discovery agent · 5 iterations · 9 confirmed findings · 25 papers reviewed · evidence current to 2026-09-29.

Artifacts

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 34
Resolved 32
Unresolved (possible confabulation) 1
Obsolete 0
Unverifiable 1
Terms whose name was checked 25
Terms named correctly 17
Terms named as a different term 5
Terms whose name is worth a second look 3

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0014148 (3 mentions) - the report calls it "if available", "MONDO"; MONDO calls it estrogen resistance syndrome
  • HP:0008819 (1 mention) - the report calls it "Abnormal pubertal development"; HP calls it Narrow femoral neck
  • HP:0002644 (1 mention) - the report calls it "Delayed epiphyseal ossification"; HP calls it Abnormal pelvic girdle bone morphology
  • HP:0000837 (1 mention) - the report calls it "Hypergonadotropic hypogonadism–related"; HP calls it Increased circulating gonadotropin level
  • HP:0003186 (1 mention) - the report calls it "Breast hypoplasia"; HP calls it Inverted nipples

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

  • HP:0000783 (1 mention), reported as "Primary amenorrhea" - HP does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • GO:0030520 (1 mention) - the report calls it "intracellular estrogen receptor signaling pathway"; GO calls it estrogen receptor signaling pathway, and lists "intracellular estrogen receptor signaling pathway" among its other names
  • GO:0006357 (1 mention) - the report calls it "regulation of transcription by RNA Pol II"; GO calls it regulation of transcription by RNA polymerase II
  • CHEBI:16469 (1 mention) - the report calls it "17β-estradiol"; CHEBI calls it 17beta-estradiol

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • MONDO:0014148 - called "if available", "MONDO"
  • CL:0000062 - called "osteoblast", "osteoblasts"
  • CL:0000138 - called "chondrocyte", "chondrocytes"
  • CL:0000501 - called "granulosa cell", "granulosa cells"

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Outcome Count
References checked 17
Resolved 17
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 14
Quoted claims found in source 10
Quoted claims not found in source 4
References weighed for topical relevance 17
On topic 10
Off topic 0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

  • PMID:32242619 (abstract only): "altered transcriptome profile"
  • Text part not found as substring: 'altered transcriptome profile' (note: only abstract available for PMID:32242619, full text may contain this excerpt)
  • PMID:32934281 (abstract only): "The direct effects of sex steroids on AMH transcription are mediated by androgen receptor and estrogen receptor α action"
  • closest text in source: "A modest action was also mediated through the membrane oestrogen receptor GPER"
  • PMID:32152632 (abstract only): "despite markedly increased estrogens"
  • Text part not found as substring: 'despite markedly increased estrogens' (note: only abstract available for PMID:32152632, full text may contain this excerpt)
  • PMID:32152632 (abstract only): "DES treatment did not induce secondary sexual characteristics in our patient. Treatment with DES was not successful in our patient. She remains hypoestrogenic"
  • closest text in source: "However, DES treatment did not induce secondary sexual characteristics in our patient"